THE FOUNDATION FOR AIDS RESEARCH: Form 990, tax year 2013
View the entire original 990 at ProPublica ↗
- Organization
- THE FOUNDATION FOR AIDS RESEARCH (EIN 13-3163817)
- Tax period
- 2013-10-01 to 2014-09-30
- Filed
- 2015-06-25
- IRS object ID
- 201541769349300449
- Schema version
- 2013v4.0
- Source
- Download XML · Original 990 at ProPublica
Every field in the e-filed return. Faint text is the IRS element name, for citing.
- Return header
- Form 990
- Schedule A
- Schedule B
- Schedule C
- Schedule D
- Schedule F
- Schedule G
- Schedule I
- Schedule J
- Schedule M
- Schedule O
Return header ReturnHeader
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return | 2015-06-25T15:00:54-05:00 | ReturnTs |
| Tax Period End | 2014-09-30 | TaxPeriodEndDt |
Preparer Firm PreparerFirmGrp
Preparer Firm Name PreparerFirmName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | GRANT THORNTON LLP | BusinessNameLine1 |
Preparer US Address PreparerUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 757 THIRD AVE 2ND FLOOR | AddressLine1 |
| City | NEW YORK | City |
| State | NY | State |
| ZIP Code | 100172013 | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return Type | 990 | ReturnTypeCd |
| Tax Period Begin | 2013-10-01 | TaxPeriodBeginDt |
Filer Filer
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN | 133163817 | EIN |
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | THE FOUNDATION FOR AIDS RESEARCH | BusinessNameLine1 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| In Care Of | % BRADLEY JENSEN | InCareOfNm |
| Business Name Control | FOUN | BusinessNameControlTxt |
| Phone | 2128061600 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 120 wall street 13TH FLOOR | AddressLine1 |
| Address Line2 | Suite | AddressLine2 |
| City | NEW YORK | City |
| State | NY | State |
| ZIP Code | 100053908 | ZIPCode |
Business Officer BusinessOfficerGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | Bradley Jensen | PersonNm |
| Person Title | CFO | PersonTitleTxt |
| Phone | 2128061703 | PhoneNum |
| Signature | 2015-06-23 | SignatureDt |
| Discuss With Paid Preparer | Yes (true) | DiscussWithPaidPreparerInd |
Preparer Person PreparerPersonGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Person | Scott Thompsett | PreparerPersonNm |
| PTIN | P00741490 | PTIN |
| Phone | 2128061703 | PhoneNum |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Tax | 2013 | TaxYr |
| Build TS | 2016-04-25 22:37:26Z | BuildTS |
Form 990 IRS990
Doing Business As Name DoingBusinessAsName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | Aids Research Foundation or AMFAR | BusinessNameLine1 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Principal Officer | KEVIN FROST | PrincipalOfficerNm |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 120 WALL STREET 13TH FLOOR | AddressLine1 |
| City | new york | City |
| State | NY | State |
| ZIP Code | 10005 | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Receipts | $77,370,757 | GrossReceiptsAmt |
| Group Return For Affiliates | false | GroupReturnForAffiliatesInd |
| Organization501c3 | Yes (X) | Organization501c3Ind |
| Website Address | WWW.AMFAR.ORG | WebsiteAddressTxt |
| Type Of Organization Corp | Yes (X) | TypeOfOrganizationCorpInd |
| Formation | 1983 | FormationYr |
| Legal Domicile State | NY | LegalDomicileStateCd |
| Activity Or Mission | amfar is dedicated to ending the global AIDS EPIDEMIC THROUGH INNOVATIVE RESEARCH. | ActivityOrMissionDesc |
| Voting Members Governing Body | 20 | VotingMembersGoverningBodyCnt |
| Voting Members Independent | 20 | VotingMembersIndependentCnt |
| Total Employee | 92 | TotalEmployeeCnt |
| Total Volunteers | 160 | TotalVolunteersCnt |
| Total Gross UBI | $0 | TotalGrossUBIAmt |
| PY Contributions Grants | $38,582,579 | PYContributionsGrantsAmt |
| CY Contributions Grants | $57,556,516 | CYContributionsGrantsAmt |
| PY Program Service Revenue | $0 | PYProgramServiceRevenueAmt |
| CY Program Service Revenue | $0 | CYProgramServiceRevenueAmt |
| PY Investment Income | $980,398 | PYInvestmentIncomeAmt |
| CY Investment Income | $1,225,465 | CYInvestmentIncomeAmt |
| PY Other Revenue | -$9,648,345 | PYOtherRevenueAmt |
| CY Other Revenue | -$10,881,866 | CYOtherRevenueAmt |
| PY Total Revenue | $29,914,632 | PYTotalRevenueAmt |
| CY Total Revenue | $47,900,115 | CYTotalRevenueAmt |
| PY Grants And Similar Paid | $7,997,283 | PYGrantsAndSimilarPaidAmt |
| CY Grants And Similar Paid | $9,928,384 | CYGrantsAndSimilarPaidAmt |
| PY Benefits Paid To Members | $0 | PYBenefitsPaidToMembersAmt |
| CY Benefits Paid To Members | $0 | CYBenefitsPaidToMembersAmt |
| PY Salaries Comp Emp Bnft Paid | $9,333,804 | PYSalariesCompEmpBnftPaidAmt |
| CY Salaries Comp Emp Bnft Paid | $9,582,859 | CYSalariesCompEmpBnftPaidAmt |
| PY Total Prof Fndrsng Expns | $470,337 | PYTotalProfFndrsngExpnsAmt |
| CY Total Prof Fndrsng Expns | $569,004 | CYTotalProfFndrsngExpnsAmt |
| CY Total Fundraising Expense | $5,153,653 | CYTotalFundraisingExpenseAmt |
| PY Other Expenses | $11,457,241 | PYOtherExpensesAmt |
| CY Other Expenses | $14,312,877 | CYOtherExpensesAmt |
| PY Total Expenses | $29,258,665 | PYTotalExpensesAmt |
| CY Total Expenses | $34,393,124 | CYTotalExpensesAmt |
| PY Revenues Less Expenses | $655,967 | PYRevenuesLessExpensesAmt |
| CY Revenues Less Expenses | $13,506,991 | CYRevenuesLessExpensesAmt |
| Total Assets BOY | $50,024,337 | TotalAssetsBOYAmt |
| Total Assets EOY | $57,895,971 | TotalAssetsEOYAmt |
| Total Liabilities BOY | $18,892,314 | TotalLiabilitiesBOYAmt |
| Total Liabilities EOY | $13,585,624 | TotalLiabilitiesEOYAmt |
| Net Assets Or Fund Balances BOY | $31,132,023 | NetAssetsOrFundBalancesBOYAmt |
| Net Assets Or Fund Balances EOY | $44,310,347 | NetAssetsOrFundBalancesEOYAmt |
| Info In Schedule O Part III | Yes (X) | InfoInScheduleOPartIIIInd |
| Mission | THE FOUNDATION FOR AIDS RESEARCH IS AN INTERNATIONAL NOT-FOR-PROFIT ORGANIZATION INCORPORATED IN NEW YORK IN 1989. AMFAR WAS FORMED THROUGH THE UNIFICATION IN 1985 OF TWO NOT-FOR-PROFIT ORGANIZATIONS, THE AIDS MEDICAL FOUNDATION ("AMF"), INCORPORATED IN NEW YORK IN APRIL 1983, AND THE NATIONAL AIDS RESEARCH FOUNDATION, INCORPORATED IN CALIFORNIA IN AUGUST 1985. FIRST BASED IN CALIFORNIA, AMFAR TRANSFERRED ITS LEGAL DOMICILE TO NEW YORK IN 1989, USING THE INITIAL INCORPORATION DOCUMENTS OF AMF, MAKING IT AMF'S LEGAL SUCCESSOR. AMFAR HAS OFFICES IN NEW YORK, NY, WASHINGTON, D.C., AND BANGKOK, THAILAND. ON MARCH 7, 2005, THE BOARD OF TRUSTEES OF THE AMERICAN FOUNDATION FOR AIDS RESEARCH APPROVED A CHANGE IN LEGAL NAME TO "THE FOUNDATION FOR AIDS RESEARCH." ON OCTOBER 18, 2005, THE NEW YORK STATE DEPARTMENT OF STATE APPROVED THIS CHANGE. IN ADDITION, THE FOUNDATION HAS SECURED APPROVAL FOR DOING BUSINESS AS (DBA) THE FOLLOWING: - AMERICAN FOUNDATION FOR AIDS RESEARCH - AMFAR - AIDS RESEARC | MissionDesc |
| Significant New Program Srvc | false | SignificantNewProgramSrvcInd |
| Significant Change | false | SignificantChangeInd |
| Expense | $11,765,284 | ExpenseAmt |
| Grant | $5,482,076 | GrantAmt |
| Revenue | $0 | RevenueAmt |
| Desc | RESEARCH: amfAR supports research projects that explore novel approaches to scientifically sound but untested hypotheses in all areas of research on HIV/AIDS, funding goal-oriented studies that often lack the preliminary data required for support from traditional grant-makers. The Foundation plays a vital role in HIV/AIDS research, identifying critical gaps in knowledge and providing essential seed money that enables grantees and fellows to test the merits of new concepts or technologies that subsequently can be validated through large-scale studies, such as those funded by the National Institutes of Health. FOR FURTHER DETAILS, SEE SCHEDULE O. | Desc |
Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $6,754,069 | ExpenseAmt |
| Grant | $3,275,924 | GrantAmt |
| Revenue | $0 | RevenueAmt |
| Desc | TREAT ASIA: amfAR's TREAT Asia program (Therapeutics Research, Education, and AIDS Training in Asia) involves a network of hospitals, clinics, and research institutions working with civil society to ensure the safe and effective delivery of HIV/AIDS treatments across Asia and the Pacific. The TREAT Asia Network encompasses 21 adult and 18 pediatric sites throughout the region, which collaborate on a variety of projects. FOR FURTHER DETAILS, SEE SCHEDULE O. | Desc |
Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $3,625,752 | ExpenseAmt |
| Grant | $0 | GrantAmt |
| Revenue | $0 | RevenueAmt |
| Desc | EDUCATION AND INFORMATION: amfAR seeks to translate and disseminate information on important AIDS-related research, treatment, prevention, and policy issues for diverse audiences and to increase broad awareness and knowledge of the pandemic. amfAR also publishes a wide range of educational materials, maintains an informative website, and engages respected public figures, HIV/AIDS scientists, and policymakers in communicating the need for continued research on HIV/AIDS. FOR FURTHER DETAILS, SEE SCHEDULE O. | Desc |
Prog Srvc Accom Acty Other ProgSrvcAccomActyOtherGrp (2 entries)
| ExpenseExpenseAmt | GrantGrantAmt | RevenueRevenueAmt | DescDesc |
|---|---|---|---|
| $2,388,396 | $875,445 | $0 | GMT Initiative |
| $2,233,490 | $294,939 | $0 | public policy |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Other Prog Srvc Expense | $4,621,886 | TotalOtherProgSrvcExpenseAmt |
| Total Other Prog Srvc Grant | $1,170,384 | TotalOtherProgSrvcGrantAmt |
| Total Other Prog Srvc Revenue | $0 | TotalOtherProgSrvcRevenueAmt |
| Total Program Service Expenses | $26,766,991 | TotalProgramServiceExpensesAmt |
| Described In Section501c3 | Yes (true) | DescribedInSection501c3Ind |
| Schedule B Required | Yes (true) | ScheduleBRequiredInd |
| Political Campaign Acty | false | PoliticalCampaignActyInd |
| Lobbying Activities | Yes (true) | LobbyingActivitiesInd |
| Subject To Proxy Tax | false | SubjectToProxyTaxInd |
| Donor Advised Fund | false | DonorAdvisedFundInd |
| Conservation Easements | false | ConservationEasementsInd |
| Collections Of Art | Yes (true) | CollectionsOfArtInd |
| Credit Counseling | false | CreditCounselingInd |
| Temp Or Permanent Endowments | Yes (true) | TempOrPermanentEndowmentsInd |
| Report Land Building Equipment | Yes (true) | ReportLandBuildingEquipmentInd |
| Report Investments Other Sec | false | ReportInvestmentsOtherSecInd |
| Report Program Related Invst | false | ReportProgramRelatedInvstInd |
| Report Other Assets | false | ReportOtherAssetsInd |
| Report Other Liabilities | Yes (true) | ReportOtherLiabilitiesInd |
| Include FIN48 Footnote | Yes (true) | IncludeFIN48FootnoteInd |
| Independent Audit Fincl Stmt | Yes (true) | IndependentAuditFinclStmtInd |
| Consolidated Audit Fincl Stmt | false | ConsolidatedAuditFinclStmtInd |
| School Operating | false | SchoolOperatingInd |
| Foreign Office | Yes (true) | ForeignOfficeInd |
| Foreign Activities | Yes (true) | ForeignActivitiesInd |
| More Than5000 K To Org | Yes (true) | MoreThan5000KToOrgInd |
| More Than5000 K To Individuals | false | MoreThan5000KToIndividualsInd |
| Professional Fundraising | Yes (true) | ProfessionalFundraisingInd |
| Fundraising Activities | Yes (true) | FundraisingActivitiesInd |
| Gaming Activities | false | GamingActivitiesInd |
| Operate Hospital | false | OperateHospitalInd |
| Grants To Organizations | Yes (true) | GrantsToOrganizationsInd |
| Grants To Individuals | false | GrantsToIndividualsInd |
| Schedule J Required | Yes (true) | ScheduleJRequiredInd |
| Tax Exempt Bonds | false | TaxExemptBondsInd |
| Engaged In Excess Benefit Trans | false | EngagedInExcessBenefitTransInd |
| PY Excess Benefit Trans | false | PYExcessBenefitTransInd |
| Loan Outstanding | false | LoanOutstandingInd |
| Grant To Related Person | false | GrantToRelatedPersonInd |
| Business Rln With Org Mem | false | BusinessRlnWithOrgMemInd |
| Business Rln With Fam Mem | false | BusinessRlnWithFamMemInd |
| Business Rln With Officer Ent | false | BusinessRlnWithOfficerEntInd |
| Deductible Non Cash Contri | Yes (true) | DeductibleNonCashContriInd |
| Deductible Art Contribution | false | DeductibleArtContributionInd |
| Terminate Operations | false | TerminateOperationsInd |
| Partial Liquidation | false | PartialLiquidationInd |
| Disregarded Entity | false | DisregardedEntityInd |
| Related Entity | false | RelatedEntityInd |
| Related Organization Ctrl Ent | false | RelatedOrganizationCtrlEntInd |
| Trnsfr Exmpt Non Chrtbl Rltd Org | false | TrnsfrExmptNonChrtblRltdOrgInd |
| Activities Conducted Prtshp | false | ActivitiesConductedPrtshpInd |
| Schedule O Required | Yes (true) | ScheduleORequiredInd |
| IRP Document | 112 | IRPDocumentCnt |
| IRP Document W2 G | 0 | IRPDocumentW2GCnt |
| Backup Wthld Compliance | Yes (true) | BackupWthldComplianceInd |
| Employee | 92 | EmployeeCnt |
| Employment Tax Returns Filed | Yes (true) | EmploymentTaxReturnsFiledInd |
| Unrelated Bus Incm Over Limit | false | UnrelatedBusIncmOverLimitInd |
| Foreign Financial Account | Yes (true) | ForeignFinancialAccountInd |
| Foreign Country | TH | ForeignCountryCd |
| Prohibited Tax Shelter Trans | false | ProhibitedTaxShelterTransInd |
| Taxable Party Notification | false | TaxablePartyNotificationInd |
| Nondeductible Contributions | false | NondeductibleContributionsInd |
| Quid Pro Quo Contributions | Yes (true) | QuidProQuoContributionsInd |
| Quid Pro Quo Contri Discl | Yes (true) | QuidProQuoContriDisclInd |
| Form8282 Property Disposed Of | false | Form8282PropertyDisposedOfInd |
| Rcv Fnds To Pay Prsnl Bnft Cntrct | false | RcvFndsToPayPrsnlBnftCntrctInd |
| Pay Premiums Prsnl Bnft Cntrct | false | PayPremiumsPrsnlBnftCntrctInd |
| Indoor Tanning Services | false | IndoorTanningServicesInd |
| Info In Schedule O Part VI | Yes (X) | InfoInScheduleOPartVIInd |
| Governing Body Voting Members | 20 | GoverningBodyVotingMembersCnt |
| Independent Voting Member | 20 | IndependentVotingMemberCnt |
| Family Or Business Rln | false | FamilyOrBusinessRlnInd |
| Delegation Of Mgmt Duties | false | DelegationOfMgmtDutiesInd |
| Change To Org Documents | false | ChangeToOrgDocumentsInd |
| Material Diversion Or Misuse | false | MaterialDiversionOrMisuseInd |
| Members Or Stockholders | false | MembersOrStockholdersInd |
| Election Of Board Members | false | ElectionOfBoardMembersInd |
| Decisions Subject To Approva | false | DecisionsSubjectToApprovaInd |
| Minutes Of Governing Body | Yes (true) | MinutesOfGoverningBodyInd |
| Minutes Of Committees | Yes (true) | MinutesOfCommitteesInd |
| Officer Mailing Address | false | OfficerMailingAddressInd |
| Local Chapters | false | LocalChaptersInd |
| Form990 Provided To Gvrn Body | Yes (true) | Form990ProvidedToGvrnBodyInd |
| Conflict Of Interest Policy | Yes (true) | ConflictOfInterestPolicyInd |
| Annual Disclosure Covered Prsn | Yes (true) | AnnualDisclosureCoveredPrsnInd |
| Regular Monitoring Enfrc | Yes (true) | RegularMonitoringEnfrcInd |
| Whistleblower Policy | Yes (true) | WhistleblowerPolicyInd |
| Document Retention Policy | Yes (true) | DocumentRetentionPolicyInd |
| Compensation Process CEO | Yes (true) | CompensationProcessCEOInd |
| Compensation Process Other | Yes (true) | CompensationProcessOtherInd |
| Investment In Joint Venture | false | InvestmentInJointVentureInd |
| States Where Copy Of Return Is Fld | AL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | AK | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | AR | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | CA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | CO | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | CT | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | FL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | GA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | HI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | IL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | KS | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | KY | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | LA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | ME | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MD | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MN | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MS | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NH | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NJ | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NM | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NY | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NC | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | OH | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | OK | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | OR | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | PA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | RI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | SC | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | TN | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | UT | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | VA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | WV | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | WI | StatesWhereCopyOfReturnIsFldCd |
| Own Website | Yes (X) | OwnWebsiteInd |
| Upon Request | Yes (X) | UponRequestInd |
Books In Care Of Detail BooksInCareOfDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | BRADLEY JENSEN | PersonNm |
| Phone | 2128061703 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 120 WALL STREET 13TH FLOOR | AddressLine1 |
| City | new york | City |
| State | NY | State |
| ZIP Code | 100053908 | ZIPCode |
Form990 Part VII Section A Form990PartVIISectionAGrp (42 entries)
| TitleTitleTxt | Average Hours Per WeekAverageHoursPerWeekRt | Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd | OfficerOfficerInd | Reportable Comp From OrgReportableCompFromOrgAmt | Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt | Other CompensationOtherCompensationAmt | Key EmployeeKeyEmployeeInd | Highest Compensated EmployeeHighestCompensatedEmployeeInd | Former Ofcr Director TrusteeFormerOfcrDirectorTrusteeInd |
|---|---|---|---|---|---|---|---|---|---|
| Mathilde Krim PhD | |||||||||
| Founding Chairman | 1.0 | Yes (X) | Yes (X) | $0 | $0 | $0 | |||
| Kenneth Cole | |||||||||
| Chairman of the Board | 1.0 | Yes (X) | Yes (X) | $0 | $0 | $0 | |||
| Patricia J Matson | |||||||||
| Vice Chairman | 1.0 | Yes (X) | Yes (X) | ||||||
| John C Simons | |||||||||
| Vice Chairman | 1.0 | Yes (X) | Yes (X) | ||||||
| Wallace Sheft CPA | |||||||||
| Treasurer | 1.0 | Yes (X) | Yes (X) | ||||||
| Mervyn F Silverman MDMPH | |||||||||
| Secretary | 1.0 | Yes (X) | Yes (X) | ||||||
| Arlen H Andelson | |||||||||
| Trustee | 1.0 | Yes (X) | |||||||
| Harry Belafonte | |||||||||
| Trustee (NON-VOTING) | 1.0 | Yes (X) | |||||||
| David Bohnett | |||||||||
| Trustee | 1.0 | Yes (X) | |||||||
| Zev Braun | |||||||||
| Trustee (NON-VOTING) | 1.0 | Yes (X) | |||||||
| Jonathan S Canno | |||||||||
| Trustee | 1.0 | Yes (X) | |||||||
| Donald Capoccia | |||||||||
| Trustee | 1.0 | Yes (X) | |||||||
| R Martin Chavez PhD | |||||||||
| Trustee | 1.0 | Yes (X) | |||||||
| Jane B Eisner | |||||||||
| Trustee (NON-VOTING) | 1.0 | Yes (X) | |||||||
| T Ryan Greenawalt | |||||||||
| Trustee | 1.0 | Yes (X) | |||||||
| Regan Hofmann | |||||||||
| Trustee | 1.0 | Yes (X) | |||||||
| Michael J Klingensmith | |||||||||
| Trustee | 1.0 | Yes (X) | |||||||
| Kevin McClatchy | |||||||||
| Trustee | 1.0 | Yes (X) | |||||||
| Michele V McNeill PharmD | |||||||||
| Trustee (NON-VOTING) | 1.0 | Yes (X) | |||||||
| Edward Milstein | |||||||||
| Trustee | 1.0 | Yes (X) | |||||||
| Cindy Rachofsky | |||||||||
| Trustee | 1.0 | Yes (X) | |||||||
| Vincent A Roberti | |||||||||
| Trustee | 1.0 | Yes (X) | |||||||
| Bill Roedy | |||||||||
| Trustee | 1.0 | Yes (X) | |||||||
| Raymond F Schinazi PhD | |||||||||
| Trustee | 1.0 | Yes (X) | |||||||
| Alan D Schwartz | |||||||||
| Trustee (NON-VOTING) | 1.0 | Yes (X) | |||||||
| Diana L Taylor | |||||||||
| Trustee (NON-VOTING) | 1.0 | Yes (X) | $0 | $0 | $0 | ||||
| Kevin Wendle | |||||||||
| Trustee (NON-VOTING) | 1.0 | Yes (X) | |||||||
| Kevin Frost | |||||||||
| Chief Executive Officer | 40.0 | Yes (X) | $411,466 | $140,181 | |||||
| Bradley Jensen | |||||||||
| Assistant Treasurer, Cfo | 40.0 | Yes (X) | $225,977 | $51,151 | |||||
| John F Logan JD PhD | |||||||||
| AssT Sec, Vp, GEN COUNSEL | 40.0 | Yes (X) | $210,168 | $26,323 | |||||
| Rowena Johnston | |||||||||
| AsSt Secretary, Vice PresIDENT | 40.0 | Yes (X) | $173,783 | $23,624 | |||||
| Edward Donnelly | |||||||||
| Asst Treasurer, ControlleR | 40.0 | Yes (X) | $139,447 | $20,664 | |||||
| Eric Muscatell | |||||||||
| Vice President of Development | 40.0 | $164,114 | $23,146 | Yes (X) | |||||
| Christopher Collins | |||||||||
| Vice President, Public Policy | 40.0 | $190,478 | $48,545 | Yes (X) | |||||
| Annette Sohn | |||||||||
| Vice President, TREAT Asia PGM | 40.0 | $200,792 | $20,081 | Yes (X) | |||||
| AnnMarie Shannahan | |||||||||
| Vice President, Public Info. | 40.0 | $200,861 | $25,569 | Yes (X) | |||||
| Andrew McInness | |||||||||
| Director, Publications | 40.0 | $142,695 | $45,333 | Yes (X) | |||||
| Anthony Ancona | |||||||||
| Vice President, Human Resource | 40.0 | $158,957 | $22,792 | Yes (X) | |||||
| Susan Doster | |||||||||
| Chief Technology Officer | 40.0 | $132,756 | $25,489 | Yes (X) | |||||
| Bennah Serfaty | |||||||||
| Sr Director of CommunicatiON | 40.0 | $113,800 | $43,226 | Yes (X) | |||||
| Raoul Norman Tenazas | |||||||||
| Creative Director | 40.0 | $110,187 | $43,099 | Yes (X) | |||||
| GREGORY L BOROFF | |||||||||
| VP, DEVELOPMENT | 40.0 | $155,189 | $17,649 | Yes (X) | |||||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Reportable Comp From Org | $2,730,670 | TotalReportableCompFromOrgAmt |
| Tot Reportable Comp Rltd Org | $0 | TotReportableCompRltdOrgAmt |
| Total Other Compensation | $576,872 | TotalOtherCompensationAmt |
| Indiv Rcvd Greater Than100 K | 18 | IndivRcvdGreaterThan100KCnt |
| Former Ofcr Employees Listed | Yes (true) | FormerOfcrEmployeesListedInd |
| Total Comp Greater Than150 K | Yes (true) | TotalCompGreaterThan150KInd |
| Compensation From Other Srcs | false | CompensationFromOtherSrcsInd |
Contractor Compensation ContractorCompensationGrp (5 entries)
| Address Line1ContractorAddress/USAddress/AddressLine1 | CityContractorAddress/USAddress/City | StateContractorAddress/USAddress/State | ZIP CodeContractorAddress/USAddress/ZIPCode | ServicesServicesDesc | CompensationCompensationAmt |
|---|---|---|---|---|---|
| Josh Woods Production | |||||
| 39 West 14th Street Suite 504 | NEW YORK | NY | 10011 | events production | $425,200 |
| AAB Productions | |||||
| 64 allen street 5th floor | NEW YORK | NY | 10002 | Events Production | $338,942 |
| The Morris King Company LLC | |||||
| 101 Fifth Avenue 8th Floor | NEW YORK | NY | 10003 | public relations | $162,000 |
| Stamp Event Management LLC | |||||
| 247 Centre Street 7th Floor | NEW YORK | NY | 10013 | Events Production | $124,418 |
| Global Health Institute | |||||
| 5530 Wisconsin Avenue Suite 1255 | CHEVY CHASE | MD | 20815 | consulting | $120,000 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Cntrct Rcvd Greater Than100 K | 7 | CntrctRcvdGreaterThan100KCnt |
| Federated Campaigns | $376,242 | FederatedCampaignsAmt |
| Fundraising | $39,937,861 | FundraisingAmt |
| Government Grants | $7,391,835 | GovernmentGrantsAmt |
| All Other Contributions | $9,850,578 | AllOtherContributionsAmt |
| Noncash Contributions | $199,065 | NoncashContributionsAmt |
| Total Contributions | $57,556,516 | TotalContributionsAmt |
| Total Program Service Revenue | $0 | TotalProgramServiceRevenueAmt |
Investment Income InvestmentIncomeGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $740,190 | TotalRevenueColumnAmt |
| Exclusion | $740,190 | ExclusionAmt |
Incm From Invest Bond Proceeds IncmFromInvestBondProceedsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $0 | TotalRevenueColumnAmt |
Royalties Revenue RoyaltiesRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $64,176 | TotalRevenueColumnAmt |
| Exclusion | $64,176 | ExclusionAmt |
Rental Income Or Loss RentalIncomeOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Real | $0 | RealAmt |
| Personal | $0 | PersonalAmt |
Net Rental Income Or Loss NetRentalIncomeOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $0 | TotalRevenueColumnAmt |
Gross Amount Sales Assets GrossAmountSalesAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $17,316,472 | SecuritiesAmt |
Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $16,831,197 | SecuritiesAmt |
Gain Or Loss GainOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $485,275 | SecuritiesAmt |
Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $485,275 | TotalRevenueColumnAmt |
| Exclusion | $485,275 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Fundraising Gross Income | $1,448,865 | FundraisingGrossIncomeAmt |
| Contri Rpt Fundraising Event | $39,937,861 | ContriRptFundraisingEventAmt |
| Fundraising Direct Expenses | $12,639,445 | FundraisingDirectExpensesAmt |
Net Incm From Fundraising Evt NetIncmFromFundraisingEvtGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | -$11,190,580 | TotalRevenueColumnAmt |
| Exclusion | -$11,190,580 | ExclusionAmt |
Net Income From Gaming NetIncomeFromGamingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $0 | TotalRevenueColumnAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Sales Of Inventory | $239,927 | GrossSalesOfInventoryAmt |
Net Income Or Loss NetIncomeOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $239,927 | TotalRevenueColumnAmt |
| Exclusion | $239,927 | ExclusionAmt |
Other Revenue Misc OtherRevenueMiscGrp (2 entries)
| DescDesc | BusinessBusinessCd | Total Revenue ColumnTotalRevenueColumnAmt | ExclusionExclusionAmt |
|---|---|---|---|
| LIST RENTALS | 900099 | $3,116 | $3,116 |
| MISCELLANEOUS INCOME | 900099 | $1,495 | $1,495 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Revenue Total | $4,611 | OtherRevenueTotalAmt |
Total Revenue TotalRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $47,900,115 | TotalRevenueColumnAmt |
| Exclusion | -$9,656,401 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Info In Schedule O Part IX | Yes (X) | InfoInScheduleOPartIXInd |
Grants To Domestic Orgs GrantsToDomesticOrgsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $5,087,056 | TotalAmt |
| Program Services | $5,087,056 | ProgramServicesAmt |
Grants To Domestic Individuals GrantsToDomesticIndividualsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Foreign Grants ForeignGrantsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $4,841,328 | TotalAmt |
| Program Services | $4,841,328 | ProgramServicesAmt |
Benefits To Members BenefitsToMembersGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,289,885 | TotalAmt |
| Program Services | $1,661,237 | ProgramServicesAmt |
| Management And General | $305,219 | ManagementAndGeneralAmt |
| Fundraising | $323,429 | FundraisingAmt |
Comp Disqual Persons CompDisqualPersonsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Other Salaries And Wages OtherSalariesAndWagesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $5,300,415 | TotalAmt |
| Program Services | $3,564,555 | ProgramServicesAmt |
| Management And General | $578,582 | ManagementAndGeneralAmt |
| Fundraising | $1,157,278 | FundraisingAmt |
Pension Plan Contributions PensionPlanContributionsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $312,266 | TotalAmt |
| Program Services | $212,168 | ProgramServicesAmt |
| Management And General | $38,939 | ManagementAndGeneralAmt |
| Fundraising | $61,159 | FundraisingAmt |
Other Employee Benefits OtherEmployeeBenefitsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,196,548 | TotalAmt |
| Program Services | $775,429 | ProgramServicesAmt |
| Management And General | $175,700 | ManagementAndGeneralAmt |
| Fundraising | $245,419 | FundraisingAmt |
Payroll Taxes PayrollTaxesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $483,745 | TotalAmt |
| Program Services | $313,041 | ProgramServicesAmt |
| Management And General | $61,023 | ManagementAndGeneralAmt |
| Fundraising | $109,681 | FundraisingAmt |
Fees For Services Management FeesForServicesManagementGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Fees For Services Legal FeesForServicesLegalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $142,109 | TotalAmt |
| Program Services | $113,795 | ProgramServicesAmt |
| Management And General | $22,025 | ManagementAndGeneralAmt |
| Fundraising | $6,289 | FundraisingAmt |
Fees For Services Accounting FeesForServicesAccountingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $206,660 | TotalAmt |
| Management And General | $206,660 | ManagementAndGeneralAmt |
Fees For Services Lobbying FeesForServicesLobbyingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $54,005 | TotalAmt |
| Program Services | $54,005 | ProgramServicesAmt |
Fees For Services Prof Fundraising FeesForServicesProfFundraising
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $569,004 | TotalAmt |
| Fundraising | $569,004 | FundraisingAmt |
Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $181,719 | TotalAmt |
| Management And General | $181,719 | ManagementAndGeneralAmt |
Fees For Services Other FeesForServicesOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,902,283 | TotalAmt |
| Program Services | $1,373,365 | ProgramServicesAmt |
| Management And General | $55,077 | ManagementAndGeneralAmt |
| Fundraising | $473,841 | FundraisingAmt |
Advertising AdvertisingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $165,416 | TotalAmt |
| Program Services | $158,464 | ProgramServicesAmt |
| Management And General | $1,452 | ManagementAndGeneralAmt |
| Fundraising | $5,500 | FundraisingAmt |
Office Expenses OfficeExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $70,568 | TotalAmt |
| Program Services | $44,089 | ProgramServicesAmt |
| Management And General | $7,134 | ManagementAndGeneralAmt |
| Fundraising | $19,345 | FundraisingAmt |
Information Technology InformationTechnologyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $206,908 | TotalAmt |
| Program Services | $146,402 | ProgramServicesAmt |
| Management And General | $27,883 | ManagementAndGeneralAmt |
| Fundraising | $32,623 | FundraisingAmt |
Royalties RoyaltiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Occupancy OccupancyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,283,349 | TotalAmt |
| Program Services | $886,297 | ProgramServicesAmt |
| Management And General | $164,549 | ManagementAndGeneralAmt |
| Fundraising | $232,503 | FundraisingAmt |
Travel TravelGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,193,970 | TotalAmt |
| Program Services | $654,496 | ProgramServicesAmt |
| Management And General | $4,914 | ManagementAndGeneralAmt |
| Fundraising | $534,560 | FundraisingAmt |
Pymt Travel Entrtnmnt Pub Ofcl PymtTravelEntrtnmntPubOfclGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Conferences Meetings ConferencesMeetingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $834,225 | TotalAmt |
| Program Services | $740,680 | ProgramServicesAmt |
| Management And General | $12,908 | ManagementAndGeneralAmt |
| Fundraising | $80,637 | FundraisingAmt |
Interest InterestGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $59 | TotalAmt |
| Management And General | $59 | ManagementAndGeneralAmt |
Payments To Affiliates PaymentsToAffiliatesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Depreciation Depletion DepreciationDepletionGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $324,970 | TotalAmt |
| Program Services | $224,998 | ProgramServicesAmt |
| Management And General | $41,773 | ManagementAndGeneralAmt |
| Fundraising | $58,199 | FundraisingAmt |
Insurance InsuranceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $251,444 | TotalAmt |
| Program Services | $174,091 | ProgramServicesAmt |
| Management And General | $32,322 | ManagementAndGeneralAmt |
| Fundraising | $45,031 | FundraisingAmt |
Other Expenses OtherExpensesGrp (4 entries)
| DescDesc | TotalTotalAmt | Program ServicesProgramServicesAmt | Management And GeneralManagementAndGeneralAmt | FundraisingFundraisingAmt |
|---|---|---|---|---|
| PROGRAM MATERIALS | $3,328,092 | $3,328,092 | ||
| POSTAGE & SHIPPING | $801,242 | $371,668 | $5,081 | $424,493 |
| PROGRAM TECHNICAL SUPPORT | $947,234 | $947,234 | ||
| PRINTING | $670,672 | $222,662 | $525 | $447,485 |
All Other Expenses AllOtherExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,747,952 | TotalAmt |
| Program Services | $871,839 | ProgramServicesAmt |
| Management And General | $548,936 | ManagementAndGeneralAmt |
| Fundraising | $327,177 | FundraisingAmt |
Total Functional Expenses TotalFunctionalExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $34,393,124 | TotalAmt |
| Program Services | $26,766,991 | ProgramServicesAmt |
| Management And General | $2,472,480 | ManagementAndGeneralAmt |
| Fundraising | $5,153,653 | FundraisingAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Joint Costs | Yes (X) | JointCostsInd |
Total Joint Costs TotalJointCostsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,012,168 | TotalAmt |
| Program Services | $380,896 | ProgramServicesAmt |
| Fundraising | $631,272 | FundraisingAmt |
Cash Non Interest Bearing CashNonInterestBearingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $8,001,602 | BOYAmt |
| EOY | $4,961,745 | EOYAmt |
Savings And Temp Cash Invst SavingsAndTempCashInvstGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $539,347 | BOYAmt |
| EOY | $323,338 | EOYAmt |
Pledges And Grants Receivable PledgesAndGrantsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $205,706 | BOYAmt |
| EOY | $0 | EOYAmt |
Accounts Receivable AccountsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $10,267,012 | BOYAmt |
| EOY | $5,045,656 | EOYAmt |
Receivables From Officers Etc ReceivablesFromOfficersEtcGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Rcvbl From Disqualified Prsn RcvblFromDisqualifiedPrsnGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Oth Notes Loans Receivable Net OthNotesLoansReceivableNetGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Inventories For Sale Or Use InventoriesForSaleOrUseGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $133,906 | BOYAmt |
| EOY | $213,295 | EOYAmt |
Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $1,401,620 | BOYAmt |
| EOY | $1,475,828 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Land Bldg Equip Cost Or Other Bss | $5,731,579 | LandBldgEquipCostOrOtherBssAmt |
| Land Bldg Equip Accum Deprec | $3,500,879 | LandBldgEquipAccumDeprecAmt |
Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $1,975,311 | BOYAmt |
| EOY | $2,230,700 | EOYAmt |
Investments Pub Traded Sec InvestmentsPubTradedSecGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $23,656,458 | BOYAmt |
| EOY | $40,982,916 | EOYAmt |
Investments Other Securities InvestmentsOtherSecuritiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $3,169,232 | BOYAmt |
| EOY | $2,101,105 | EOYAmt |
Investments Program Related InvestmentsProgramRelatedGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Intangible Assets IntangibleAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Other Assets Total OtherAssetsTotalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $674,143 | BOYAmt |
| EOY | $561,388 | EOYAmt |
Total Assets TotalAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $50,024,337 | BOYAmt |
| EOY | $57,895,971 | EOYAmt |
Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $1,688,090 | BOYAmt |
| EOY | $2,132,495 | EOYAmt |
Grants Payable GrantsPayableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $2,200,512 | BOYAmt |
| EOY | $2,547,120 | EOYAmt |
Deferred Revenue DeferredRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $13,321,993 | BOYAmt |
| EOY | $7,166,426 | EOYAmt |
Tax Exempt Bond Liabilities TaxExemptBondLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Escrow Account Liability EscrowAccountLiabilityGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Loans From Officers Directors LoansFromOfficersDirectorsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Mortg Notes Pybl Scrd Invst Prop MortgNotesPyblScrdInvstPropGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Unsecured Notes Loans Payable UnsecuredNotesLoansPayableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Other Liabilities OtherLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $1,681,719 | BOYAmt |
| EOY | $1,739,583 | EOYAmt |
Total Liabilities TotalLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $18,892,314 | BOYAmt |
| EOY | $13,585,624 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Organization Follows SFAS117 | Yes (X) | OrganizationFollowsSFAS117Ind |
Unrestricted Net Assets UnrestrictedNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $23,555,115 | BOYAmt |
| EOY | $38,819,754 | EOYAmt |
Temporarily Rstr Net Assets TemporarilyRstrNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $7,236,209 | BOYAmt |
| EOY | $5,143,351 | EOYAmt |
Permanently Rstr Net Assets PermanentlyRstrNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $340,699 | BOYAmt |
| EOY | $347,242 | EOYAmt |
Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $31,132,023 | BOYAmt |
| EOY | $44,310,347 | EOYAmt |
Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $50,024,337 | BOYAmt |
| EOY | $57,895,971 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Info In Schedule O Part XI | Yes (X) | InfoInScheduleOPartXIInd |
| Reconcilation Revenue Expnss | $13,506,991 | ReconcilationRevenueExpnssAmt |
| Net Unrlzd Gains Losses Invst | -$295,064 | NetUnrlzdGainsLossesInvstAmt |
| Other Changes In Net Assets | -$33,603 | OtherChangesInNetAssetsAmt |
| Method Of Accounting Accrual | Yes (X) | MethodOfAccountingAccrualInd |
| Accountant Compile Or Review | false | AccountantCompileOrReviewInd |
| FS Audited | Yes (true) | FSAuditedInd |
FS Audited Basis FSAuditedBasisGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Separate Basis Fincl Stmt | Yes (X) | SeparateBasisFinclStmtInd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Audit Committee | Yes (true) | AuditCommitteeInd |
| Federal Grant Audit Required | Yes (true) | FederalGrantAuditRequiredInd |
| Federal Grant Audit Performed | Yes (true) | FederalGrantAuditPerformedInd |
Schedule A IRS990ScheduleA
| Field | Value | IRS element (for citing) |
|---|---|---|
| Public Organization170 | Yes (X) | PublicOrganization170Ind |
Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $22,553,697 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $22,876,129 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $33,247,849 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $38,582,579 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $57,556,516 | CurrentTaxYearAmt |
| Total | $174,816,770 | TotalAmt |
Tax Rev Levied Orgnztnl Bnft170 TaxRevLeviedOrgnztnlBnft170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Govt Furn Srvc Fclts Vl170 GovtFurnSrvcFcltsVl170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Total Calendar Year170 TotalCalendarYear170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $22,553,697 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $22,876,129 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $33,247,849 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $38,582,579 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $57,556,516 | CurrentTaxYearAmt |
| Total | $174,816,770 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Substantial Contributors Tot | $4,735,381 | SubstantialContributorsTotAmt |
| Public Support Total170 | $170,081,389 | PublicSupportTotal170Amt |
Gross Investment Income170 GrossInvestmentIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $668,573 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $951,963 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $897,974 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $755,293 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $804,366 | CurrentTaxYearAmt |
| Total | $4,078,169 | TotalAmt |
Unrelated Business Net Incm170 UnrelatedBusinessNetIncm170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Other Income170 OtherIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $2,756,152 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $1,735,330 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $1,624,966 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $1,467,184 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $1,693,403 | CurrentTaxYearAmt |
| Total | $9,277,035 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Support | $188,171,974 | TotalSupportAmt |
| Gross Receipts Rltd Activities | $0 | GrossReceiptsRltdActivitiesAmt |
| Public Support CY170 | 0.90386 | PublicSupportCY170Pct |
| Public Support PY170 | 0.93372 | PublicSupportPY170Pct |
| Thirty Thr Pct Suprt Tests CY170 | Yes (X) | ThirtyThrPctSuprtTestsCY170Ind |
Schedule B IRS990ScheduleB
Contributor Information ContributorInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Contributor | RESTRICTED | ContributorNum |
Contributor Business Name ContributorBusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | RESTRICTED | BusinessNameLine1 |
Contributor US Address ContributorUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | RESTRICTED | AddressLine1 |
| Address Line2 | RESTRICTED | AddressLine2 |
| City | RESTRICTED | City |
| State | RESTRICTED | State |
| ZIP Code | RESTRICTED | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Contributions | RESTRICTED | TotalContributionsAmt |
Schedule C IRS990ScheduleC
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Grassroots Lobbying | TotalGrassrootsLobbyingGrp | |
| Total Direct Lobbying | TotalDirectLobbyingGrp | |
| Total Lobbying Expend | TotalLobbyingExpendGrp | |
| Other Exempt Purpose Expend | OtherExemptPurposeExpendGrp | |
| Total Exempt Purpose Expend | TotalExemptPurposeExpendGrp | |
| Lobbying Nontaxable Amount | LobbyingNontaxableAmountGrp | |
| Grassroots Nontaxable | GrassrootsNontaxableGrp | |
| Tot Lbbyng Grassroot Mns Non Tx | TotLbbyngGrassrootMnsNonTxGrp | |
| Tot Lbby Expend Mns Lbbyng Non Tx | TotLbbyExpendMnsLbbyngNonTxGrp | |
| Volunteers | false | VolunteersInd |
| Paid Staff Or Management | Yes (true) | PaidStaffOrManagementInd |
| Media Advertisements | false | MediaAdvertisementsInd |
| Mailings Members | false | MailingsMembersInd |
| Publications Or Broadcast | false | PublicationsOrBroadcastInd |
| Grants Other Organizations | false | GrantsOtherOrganizationsInd |
| Direct Contact Legislators | false | DirectContactLegislatorsInd |
| Rallies Demonstrations | false | RalliesDemonstrationsInd |
| Other Activities | Yes (true) | OtherActivitiesInd |
| Other Activities | $179,298 | OtherActivitiesAmt |
| Total Lobbying Expenditures | $179,298 | TotalLobbyingExpendituresAmt |
| Not Described Section501c3 | false | NotDescribedSection501c3Ind |
| Form4720 Filed4912 Tax | false | Form4720Filed4912TaxInd |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | Lobbying Expenses | FormAndLineReferenceDesc |
| Explanation | Part II-B The Foundation for AIDS Research developed an Action Agenda to End AIDS that identified critical decisions that need to be made to advance evidence based AIDS policies. We created a variety of issue briefs on topics such as the potential impact of various budget scenarios on global health services, and policy priorities to address the HIV epidemic among gay men in the US. These issue briefs were shared with Capitol Hill staff and members of the Administration. amfAR met regularly with staff to members of Congress and with Administration staff, and we provided input to the Administration on development of the PEPFAR Blueprint for an AIDS Free Generation. amfAR sponsored several briefings on Capitol Hill on AIDS policy and research issues. amfAR uses these briefings as an educational tool. | ExplanationTxt |
Schedule D IRS990ScheduleD
Art Public Exhibition Amounts ArtPublicExhibitionAmountsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Assets Included | $238,050 | AssetsIncludedAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Held Works Art | HeldWorksArtGrp |
Collection Used Other Purposes CollectionUsedOtherPurposesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Collection Used Other Purposes | Yes (X) | CollectionUsedOtherPurposesInd |
| Other Purposes | Donated Items, Inventory etc. | OtherPurposesDesc |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Solicited Assets Sale | Yes (true) | SolicitedAssetsSaleInd |
CY Endwmt Fund CYEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $443,886 | BeginningYearBalanceAmt |
| Contributions | $6,543 | ContributionsAmt |
| Investment Earnings Or Losses | $40,550 | InvestmentEarningsOrLossesAmt |
| End Year Balance | $490,979 | EndYearBalanceAmt |
CY Minus1 Yr Endwmt Fund CYMinus1YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $520,804 | BeginningYearBalanceAmt |
| Contributions | $3,211 | ContributionsAmt |
| Investment Earnings Or Losses | $20,742 | InvestmentEarningsOrLossesAmt |
| Other Expenditures | $100,871 | OtherExpendituresAmt |
| End Year Balance | $443,886 | EndYearBalanceAmt |
CY Minus2 Yr Endwmt Fund CYMinus2YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $464,356 | BeginningYearBalanceAmt |
| Contributions | $4,341 | ContributionsAmt |
| Investment Earnings Or Losses | $52,107 | InvestmentEarningsOrLossesAmt |
| End Year Balance | $520,804 | EndYearBalanceAmt |
CY Minus3 Yr Endwmt Fund CYMinus3YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $561,083 | BeginningYearBalanceAmt |
| Contributions | $5,978 | ContributionsAmt |
| Investment Earnings Or Losses | -$2,705 | InvestmentEarningsOrLossesAmt |
| Other Expenditures | $100,000 | OtherExpendituresAmt |
| End Year Balance | $464,356 | EndYearBalanceAmt |
CY Minus4 Yr Endwmt Fund CYMinus4YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $516,826 | BeginningYearBalanceAmt |
| Contributions | $8,258 | ContributionsAmt |
| Investment Earnings Or Losses | $35,999 | InvestmentEarningsOrLossesAmt |
| End Year Balance | $561,083 | EndYearBalanceAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Prmnnt Endowment Balance EOY | 0.70724 | PrmnntEndowmentBalanceEOYPct |
| Term Endowment Balance EOY | 0.29276 | TermEndowmentBalanceEOYPct |
| Endowments Held Unrelated Org | false | EndowmentsHeldUnrelatedOrgInd |
| Endowments Held Related Org | false | EndowmentsHeldRelatedOrgInd |
| Land | LandGrp | |
| Buildings | BuildingsGrp |
Leasehold Improvements LeaseholdImprovementsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $2,210,687 | OtherCostOrOtherBasisAmt |
| Depreciation | $757,960 | DepreciationAmt |
| Book Value | $1,452,727 | BookValueAmt |
Equipment EquipmentGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $309,029 | OtherCostOrOtherBasisAmt |
| Depreciation | $264,410 | DepreciationAmt |
| Book Value | $44,619 | BookValueAmt |
Other Land Buildings OtherLandBuildingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $3,211,863 | OtherCostOrOtherBasisAmt |
| Depreciation | $2,478,509 | DepreciationAmt |
| Book Value | $733,354 | BookValueAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Land Buildings | $2,230,700 | TotalBookValueLandBuildingsAmt |
| Federal Income Tax Liability | $0 | FederalIncomeTaxLiabilityAmt |
Other Liabilities Org OtherLiabilitiesOrgGrp (2 entries)
| DescDesc | AmtAmt |
|---|---|
| LONG TERM LEASE LIABILITY | $1,526,258 |
| SECTION 457 RETIREMENT LIABILITIES | $213,325 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Liability | $1,739,583 | TotalLiabilityAmt |
| Footnote Text | Yes (X) | FootnoteTextInd |
| Total Rev Etc Audited Fincl Stmt | $47,761,076 | TotalRevEtcAuditedFinclStmtAmt |
| Net Unrealized Gains Invst | -$295,064 | NetUnrealizedGainsInvstAmt |
| Donated Services And Use Fclts | $189,628 | DonatedServicesAndUseFcltsAmt |
| Other Revenue | -$33,603 | OtherRevenueAmt |
| Revenue Not Reported | -$139,039 | RevenueNotReportedAmt |
| Revenue Subtotal | $47,900,115 | RevenueSubtotalAmt |
| Total Revenue Per Form990 | $47,900,115 | TotalRevenuePerForm990Amt |
| Tot Expns Etc Audited Fincl Stmt | $34,582,752 | TotExpnsEtcAuditedFinclStmtAmt |
| Donated Services Use Fclts | $189,628 | DonatedServicesUseFcltsAmt |
| Expenses Not Reported | $189,628 | ExpensesNotReportedAmt |
| Expenses Subtotal | $34,393,124 | ExpensesSubtotalAmt |
| Total Expenses Per Form990 | $34,393,124 | TotalExpensesPerForm990Amt |
Supplemental Information Detail SupplementalInformationDetail (4 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| Endowments | Part V, Line 4 AMFAR's endowment fund is intended to fund the various general research programs the organization sponsors. |
| FIN 48 | Income taxes Amfar follows guidance that clarifies the accounting for uncertainty in tax positions taken or expected to be taken in a tax return, including issues relating to financial statement recognition and guidance on measurement, classification, interest and penalties, and disclosure. As of September 30, 2014, amfar does not believe that there are any uncertain tax positions within its financial statements. Amfar has processes presently in place to ensure the maintenance of its tax-exempt status; to identify and report unrelated income; to determine its filing and tax obligations in jurisdictions for which it has nexus; and to identify and evaluate other matters that may be considered tax positions. The tax years ended 2011, 2012, 2013, and 2014 are still open to audit for both federal and state purposes. |
| reconciliation of revenue | part XI, Line 2d change in value for third party trust ($33,603) |
| Collections of Art, Historical Treasures, or other similar assets | Part III, Line 4 AMFAR holds various items of jewelry, photographs and other items of artistic value that have been donated to the organization for sale at special events. The organization has maintained these items in inventory for a few years and is in the process of selling them. |
Schedule F IRS990ScheduleF
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (true) | GrantRecordsMaintainedInd |
Account Activities Outside US AccountActivitiesOutsideUSGrp (13 entries)
| RegionRegionTxt | Type Of Activities ConductedTypeOfActivitiesConductedTxt | Specific Services ProvidedSpecificServicesProvidedTxt | Region Total ExpendituresRegionTotalExpendituresAmt | OfficesOfficesCnt | EmployeeEmployeeCnt |
|---|---|---|---|---|---|
| Central America and the Caribbean | Grantmaking | N/A | $74,955 | ||
| East Asia and the Pacific | Program Services | THERAPEUTICS RESEARCH | $2,186,834 | 1 | 19 |
| Europe (Including Iceland and Greenland) | Fundraising | n/a | $14,863,143 | ||
| North America | Grantmaking | n/a | $266,518 | ||
| Russia and the Newly Independent States | Grantmaking | n/a | $25,000 | ||
| South America | Fundraising | n/a | $1,687,171 | ||
| South Asia | Fundraising | n/a | $1,044,280 | ||
| Sub-Saharan Africa | Grantmaking | n/a | $254,310 | ||
| East Asia and the Pacific | Grantmaking | n/a | $3,063,980 | ||
| Europe (Including Iceland and Greenland) | Grantmaking | n/a | $824,303 | ||
| North America | Fundraising | n/a | $1,791 | ||
| South America | Grantmaking | n/a | $189,805 | ||
| South Asia | Grantmaking | n/a | $142,457 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Subtotal Offices | 1 | SubtotalOfficesCnt |
| Subtotal Employees | 19 | SubtotalEmployeesCnt |
| Total Office | 1 | TotalOfficeCnt |
| Total Employee | 19 | TotalEmployeeCnt |
| Subtotal Spent | $24,624,547 | SubtotalSpentAmt |
| Total Spent | $24,624,547 | TotalSpentAmt |
Grants To Org Outside US GrantsToOrgOutsideUSGrp (149 entries)
| RegionRegionTxt | Purpose Of GrantPurposeOfGrantTxt | Cash GrantCashGrantAmt | Manner Of Cash DisbursementMannerOfCashDisbursementTxt |
|---|---|---|---|
| Caribbean/Central America | GMT INITIATIVES | $10,000 | wire transfe |
| Caribbean/Central America | GMT INITIATIVES | $19,955 | wire transfe |
| Caribbean/Central America | GMT INITIATIVES | $20,000 | wire transfe |
| Caribbean/Central America | GMT INITIATIVES | $25,000 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $5,050 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $5,175 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $5,175 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $5,250 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $5,625 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $5,625 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $5,625 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $5,625 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $5,625 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $5,845 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $5,915 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $5,948 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $5,990 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $6,000 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $6,075 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $6,600 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $6,700 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $6,825 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $7,500 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $7,500 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $7,500 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $7,545 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $7,865 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $7,898 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $8,000 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $8,135 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $8,500 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $8,960 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $9,253 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $9,383 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $11,250 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $11,250 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $11,250 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $11,787 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $12,020 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $12,220 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $12,500 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $12,510 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $12,900 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $13,270 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $13,500 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $13,500 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $13,593 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $14,850 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $14,873 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $15,000 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $15,065 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $15,100 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $15,150 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $15,500 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $15,600 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $15,830 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $17,330 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $18,486 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $18,750 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $19,150 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $19,200 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $19,574 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $19,780 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $20,000 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $20,000 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $20,000 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $20,000 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $20,000 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $20,000 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $20,000 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $20,000 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $20,923 | wire transfe |
| East Asia/Pacific | GMT INITIATIVES | $25,000 | wire transfe |
| East Asia/Pacific | GMT INITIATIVES | $25,000 | wire transfe |
| East Asia/Pacific | GMT INITIATIVES | $25,000 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $25,000 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $25,200 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $26,850 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $29,515 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $30,024 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $31,388 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $32,175 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $32,515 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $33,010 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $33,010 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $34,010 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $34,035 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $35,000 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $35,000 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $41,158 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $46,905 | wire transfe |
| East Asia/Pacific | GMT INITIATIVES | $50,000 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $50,000 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $54,000 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $57,276 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $75,579 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $75,717 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $77,250 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $95,000 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $104,839 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $110,570 | wire transfe |
| East Asia/Pacific | BASIC RESEARCH | $120,000 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $192,418 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $221,907 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $227,908 | wire transfe |
| East Asia/Pacific | TREAT ASIA | $232,676 | wire transfe |
| Europe | BASIC RESEARCH | $39,066 | wire transfe |
| Europe | PUBLIC POLICY | $39,948 | wire transfe |
| Europe | PUBLIC POLICY | $50,000 | wire transfe |
| Europe | BASIC RESEARCH | $60,000 | wire transfe |
| Europe | BASIC RESEARCH | $60,000 | wire transfe |
| Europe | BASIC RESEARCH | $75,000 | wire transfe |
| Europe | BASIC RESEARCH | $75,000 | wire transfe |
| Europe | BASIC RESEARCH | $75,635 | wire transfe |
| Europe | BASIC RESEARCH | $81,852 | wire transfe |
| Europe | BASIC RESEARCH | $120,000 | wire transfe |
| Europe | BASIC RESEARCH | $147,802 | wire transfe |
| North America (excl USA) | GMT INITIATIVES | $18,000 | wire transfe |
| North America (excl USA) | BASIC RESEARCH | $118,518 | wire transfe |
| North America (excl USA) | PREVENTION SCIENCE OUTREACH | $130,000 | wire transfe |
| Russia/Newly Independent States | GMT INITIATIVES | $25,000 | wire transfe |
| South America | GMT INITIATIVES | $19,885 | wire transfe |
| South America | GMT INITIATIVES | $19,940 | wire transfe |
| South America | GMT INITIATIVES | $19,980 | wire transfe |
| South America | GMT INITIATIVES | $20,000 | wire transfe |
| South America | GMT INITIATIVES | $20,000 | wire transfe |
| South America | GMT INITIATIVES | $20,000 | wire transfe |
| South America | PREVENTION SCIENCE OUTREACH | $20,000 | wire transfe |
| South America | PREVENTION SCIENCE OUTREACH | $50,000 | wire transfe |
| South Asia | TREAT ASIA | $5,625 | wire transfe |
| South Asia | TREAT ASIA | $7,500 | wire transfe |
| South Asia | TREAT ASIA | $8,000 | wire transfe |
| South Asia | TREAT ASIA | $11,793 | wire transfe |
| South Asia | TREAT ASIA | $19,400 | wire transfe |
| South Asia | TREAT ASIA | $19,542 | wire transfe |
| South Asia | TREAT ASIA | $20,000 | wire transfe |
| South Asia | TREAT ASIA | $31,631 | wire transfe |
| Sub-Saharan Africa | GMT INITIATIVES | $12,000 | wire transfe |
| Sub-Saharan Africa | GMT INITIATIVES | $12,310 | wire transfe |
| Sub-Saharan Africa | GMT INITIATIVES | $20,000 | wire transfe |
| Sub-Saharan Africa | GMT INITIATIVES | $20,000 | wire transfe |
| Sub-Saharan Africa | GMT INITIATIVES | $20,000 | wire transfe |
| Sub-Saharan Africa | GMT INITIATIVES | $20,000 | wire transfe |
| Sub-Saharan Africa | GMT INITIATIVES | $20,000 | wire transfe |
| Sub-Saharan Africa | GMT INITIATIVES | $20,000 | wire transfe |
| Sub-Saharan Africa | GMT INITIATIVES | $25,000 | wire transfe |
| Sub-Saharan Africa | GMT INITIATIVES | $25,000 | wire transfe |
| Sub-Saharan Africa | GMT INITIATIVES | $25,000 | wire transfe |
| Sub-Saharan Africa | PUBLIC POLICY | $25,000 | wire transfe |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 149 | Total501c3OrgCnt |
| Transfer To Foreign Corp | false | TransferToForeignCorpInd |
| Interest In Foreign Trust | false | InterestInForeignTrustInd |
| Foreign Corp Ownership | false | ForeignCorpOwnershipInd |
| Passive Foreign Investmest Co | false | PassiveForeignInvestmestCoInd |
| Foreign Partnership | false | ForeignPartnershipInd |
| Boycott Countries | false | BoycottCountriesInd |
Supplemental Information Detail SupplementalInformationDetail (3 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| Foreign Activities | Part I, Line 2 International organizations are recommended for funding based upon the results of community-based peer review and/or program staff assessment of proposal merit and organization capacity to undertake proposed projects that are CHARITABLE in purpose. Pre-award due-diligence for new international grantees includes review of organization documents and registrations to verify that the organization operates for a CHARITABLE purpose and that basic capacity for project oversight and governance has been established. All international grantees are required to report semi-annually on project progress and expenditures; continued reporting is required until such time as grant funds are expended in full. Reports are reviewed by administrative and program staff. Additional oversight is provided as necessary by means of ongoing, informal contact with sites regarding progress and technical issues and site visits where feasible. International research grant recipients submit an interim and a final progress reporting addition to expenditures reports due following the ends of the 2nd, 3rd and final quarters of the performance period. |
| foreign activities | Part I, Line 3, Column D The Foundation for AIDS Research conducts many of its grant-making program services (see Part III of Form 990) in U.S. and foreign jurisdictions. In column D, the organization has reported the basic program these grants support; please refer to Part III for more information about these programs/initiatives. |
| Foreign Activities - Status of Grantees | The Foundation for Aids Research supports many non-U.S. organizations in the fight against AIDS and HIV-related diseases. For purposes of Schedule F, Part II, Line 2 - all 149 charities supported are presumed to be the equivalent of U.S. charities. |
Schedule G IRS990ScheduleG
| Field | Value | IRS element (for citing) |
|---|---|---|
| Mail Solicitations | Yes (X) | MailSolicitationsInd |
| Email Solicitations | Yes (X) | EmailSolicitationsInd |
| Phone Solicitations | Yes (X) | PhoneSolicitationsInd |
| Solicitation Of Non Govt Grants | Yes (X) | SolicitationOfNonGovtGrantsInd |
| Solicitation Of Govt Grants | Yes (X) | SolicitationOfGovtGrantsInd |
| Special Fundraising Events | Yes (X) | SpecialFundraisingEventsInd |
| Agrmt Prof Fundraising Acty | Yes (true) | AgrmtProfFundraisingActyInd |
Fundraiser Activity Info FundraiserActivityInfoGrp (4 entries)
| Address Line1USAddress/AddressLine1 | Address Line2USAddress/AddressLine2 | CityUSAddress/City | StateUSAddress/State | ZIP CodeUSAddress/ZIPCode | ActivityActivityTxt | Fundraiser Control Of FundsFundraiserControlOfFundsInd | Gross ReceiptsGrossReceiptsAmt | Retained By ContractorRetainedByContractorAmt | Net To OrganizationNetToOrganizationAmt |
|---|---|---|---|---|---|---|---|---|---|
| aab productions | |||||||||
| 387 GRANT STREET | SUITE K705 | NEW YORK | NY | 10002 | events production | false | $31,238,437 | $555,619 | $30,682,818 |
| EIDOLON COMMUNICATIONS INC | |||||||||
| 15 MAIDEN LANE SUITE 1401 | NEW YORK | NY | 10038 | direct mail | false | $2,023,625 | $228,493 | $1,795,132 | |
| public interest communications | |||||||||
| 7700 LEESBURG PIKE | FALLS CHURCH | VA | 22043 | tele marketing | false | $14,927 | $39,032 | -$24,105 | |
| SANKY COMMUNICATIONS INC | |||||||||
| 589 EIGHT AVENUE 10TH FLOOR | NEW YORK | NY | 10018 | TELE MARKETING | false | $353,939 | $57,810 | $296,129 | |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Gross Receipts | $33,630,928 | TotalGrossReceiptsAmt |
| Total Retained By Contractors | $880,954 | TotalRetainedByContractorsAmt |
| Total Net To Organization | $32,749,974 | TotalNetToOrganizationAmt |
| Licensed States | AL | LicensedStatesCd |
| Licensed States | AK | LicensedStatesCd |
| Licensed States | AR | LicensedStatesCd |
| Licensed States | CA | LicensedStatesCd |
| Licensed States | CO | LicensedStatesCd |
| Licensed States | CT | LicensedStatesCd |
| Licensed States | DC | LicensedStatesCd |
| Licensed States | FL | LicensedStatesCd |
| Licensed States | GA | LicensedStatesCd |
| Licensed States | HI | LicensedStatesCd |
| Licensed States | IL | LicensedStatesCd |
| Licensed States | KS | LicensedStatesCd |
| Licensed States | KY | LicensedStatesCd |
| Licensed States | LA | LicensedStatesCd |
| Licensed States | ME | LicensedStatesCd |
| Licensed States | MD | LicensedStatesCd |
| Licensed States | MA | LicensedStatesCd |
| Licensed States | MI | LicensedStatesCd |
| Licensed States | MN | LicensedStatesCd |
| Licensed States | MS | LicensedStatesCd |
| Licensed States | MO | LicensedStatesCd |
| Licensed States | NV | LicensedStatesCd |
| Licensed States | NH | LicensedStatesCd |
| Licensed States | NJ | LicensedStatesCd |
| Licensed States | NM | LicensedStatesCd |
| Licensed States | NY | LicensedStatesCd |
| Licensed States | NC | LicensedStatesCd |
| Licensed States | ND | LicensedStatesCd |
| Licensed States | OH | LicensedStatesCd |
| Licensed States | OK | LicensedStatesCd |
| Licensed States | OR | LicensedStatesCd |
| Licensed States | PA | LicensedStatesCd |
| Licensed States | RI | LicensedStatesCd |
| Licensed States | SC | LicensedStatesCd |
| Licensed States | TN | LicensedStatesCd |
| Licensed States | TX | LicensedStatesCd |
| Licensed States | UT | LicensedStatesCd |
| Licensed States | VA | LicensedStatesCd |
| Licensed States | WA | LicensedStatesCd |
| Licensed States | WV | LicensedStatesCd |
| Licensed States | WI | LicensedStatesCd |
Fundraising Event Information FundraisingEventInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Name Of Event1 | CANNES | NameOfEvent1Amt |
| Gross Receipts Event1 | $24,869,711 | GrossReceiptsEvent1Amt |
| Charitable Contri Event1 | $24,424,711 | CharitableContriEvent1Amt |
| Gross Revenue Event1 | $445,000 | GrossRevenueEvent1Amt |
| Rent Facility Costs Event1 | $1,333,994 | RentFacilityCostsEvent1Amt |
| Food And Beverage Event1 | $238,238 | FoodAndBeverageEvent1Amt |
| Entertainment Event1 | $1,218,319 | EntertainmentEvent1Amt |
| Other Direct Expenses Event1 | $3,748,981 | OtherDirectExpensesEvent1Amt |
| Name Of Event2 | DALLAS | NameOfEvent2Amt |
| Gross Receipts Event2 | $3,074,959 | GrossReceiptsEvent2Amt |
| Charitable Contri Event2 | $2,966,759 | CharitableContriEvent2Amt |
| Gross Revenue Event2 | $108,200 | GrossRevenueEvent2Amt |
| Rent Facility Costs Event2 | $283,704 | RentFacilityCostsEvent2Amt |
| Food And Beverage Event2 | $178,033 | FoodAndBeverageEvent2Amt |
| Entertainment Event2 | $84,797 | EntertainmentEvent2Amt |
| Other Direct Expenses Event2 | $481,108 | OtherDirectExpensesEvent2Amt |
| Other Events Total | 17 | OtherEventsTotalCnt |
| Gross Receipts Other Events | $13,442,056 | GrossReceiptsOtherEventsAmt |
| Charitable Contri Other Events | $12,546,391 | CharitableContriOtherEventsAmt |
| Gross Revenue Other Events | $895,665 | GrossRevenueOtherEventsAmt |
| Rent Fclty Costs Other Events | $348,100 | RentFcltyCostsOtherEventsAmt |
| Food And Beverage Other Events | $641,481 | FoodAndBeverageOtherEventsAmt |
| Entertainment Other Events | $1,804,451 | EntertainmentOtherEventsAmt |
| Oth Direct Expnss Other Events | $2,278,239 | OthDirectExpnssOtherEventsAmt |
| Gross Receipts Total | $41,386,726 | GrossReceiptsTotalAmt |
| Charitable Contributions Tot | $39,937,861 | CharitableContributionsTotAmt |
| Gross Revenue Total Events | $1,448,865 | GrossRevenueTotalEventsAmt |
| Rent Fclty Costs Total Events | $1,965,798 | RentFcltyCostsTotalEventsAmt |
| Food And Beverage Total Events | $1,057,752 | FoodAndBeverageTotalEventsAmt |
| Entertainment Total Events | $3,107,567 | EntertainmentTotalEventsAmt |
| Oth Direct Expnss Total Events | $6,508,328 | OthDirectExpnssTotalEventsAmt |
| Direct Expense Summary Events | $12,639,445 | DirectExpenseSummaryEventsAmt |
| Net Income Summary | -$11,190,580 | NetIncomeSummaryAmt |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | Schedule G, Part I | FormAndLineReferenceDesc |
| Explanation | The Foundation for AIDS Research actually paid out $569,004 in fundraising expenses for the year ending September 30, 2014. This amount is reported on Part IX, Line 11(e). For purposes of Schedule G, the Foundation is reporting all amounts paid to the consultants listed on Part I, regardless of whether such amounts were pure fundraising expenses or event production costs. On Schedule G, the total amount paid to the organizations listed is $880,954. Of that $880,954, only $569,004 was paid for fundraising services, the remaining $311,950 was paid for event production services. In the interests of clarity, the foundation would also like to make clear that the compensation reported as having been paid to the professional fundraisers reported on Schedule G is reported on a fiscal year basis. Some of those same fundraisers are reported on the foundation's top 5 highest paid independent contractors list (in Schedule O). In compliance with the instructions to the Form 990, compensation reported for Part VII (and listed in Schedule O) is reported on a calendar year basis. Accordingly, amounts on Part VII and Schedule G will not reconcile. | ExplanationTxt |
Schedule I IRS990ScheduleI
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (true) | GrantRecordsMaintainedInd |
Recipient Table RecipientTable (63 entries)
| Address Line1USAddress/AddressLine1 | CityUSAddress/City | StateUSAddress/State | ZIP CodeUSAddress/ZIPCode | Recipient EINRecipientEIN | IRC SectionIRCSectionDesc | Cash GrantCashGrantAmt | Purpose Of GrantPurposeOfGrantTxt |
|---|---|---|---|---|---|---|---|
| Vaccine & Gene Therapy Institute of Florida | |||||||
| 11350 SW Village Pkwy | Pt St Lucie | FL | 34987 | 364631835 | 501(c)(3) | $5,209 | BASIC RESEARCH |
| University of Washington | |||||||
| 4333 Brooklyn Avenue | Seattle | WA | 981959472 | 916001537 | 501(c)(3) | $5,209 | BASIC RESEARCH |
| Vaccine & Gene Therapy Institute of Florida | |||||||
| 11350 SW Village Pkwy | Pt St Lucie | FL | 34987 | 364631835 | 501(c)(3) | $5,209 | BASIC RESEARCH |
| Case Western Reserve University | |||||||
| 10900 Euclid Ave | Cleveland | OH | 44106 | 341018992 | 501(c)(3) | $5,209 | BASIC RESEARCH |
| AIDS Foundation of Chicago | |||||||
| 200 West Jackson Ste 2200 | Chicago | IL | 60606 | 363412054 | 501(c)(3) | $10,000 | MSM INITIATIVES |
| AIDS Project Los Angeles (APLA) | |||||||
| 611 S Kingsley Drive | Los Angeles | CA | 90005 | 953842506 | 501(c)(3) | $10,000 | MSM INITIATIVES |
| Case Western Reserve University | |||||||
| 10900 Euclid Ave | Cleveland | OH | 44106 | 341018992 | 501(c)(3) | $15,620 | BASIC RESEARCH |
| Aaron Diamond AIDS Research Center | |||||||
| 455 1st Ave 7th Fl | New York | NY | 10016 | 133540234 | 501(c)(3) | $15,626 | BASIC RESEARCH |
| New England Primate Research Center | |||||||
| Harvard Medical School 25 Shattuck | Southborough | MA | 01772 | 042103580 | 501(c)(3) | $15,626 | BASIC RESEARCH |
| AIDS Resource Center Ohio | |||||||
| 15 W 4th St No 200 | Dayton | OH | 45402 | 311126780 | 501(c)(3) | $20,000 | PUBLIC POLICY |
| AIDS Foundation of Chicago | |||||||
| 200 W Jackson Ste 2200 | Chicago | IL | 60606 | 363412054 | 501(c)(3) | $20,000 | PUBLIC POLICY |
| Baron Edmond de Rothschild Chemical Dep | |||||||
| 1st Ave at 16th St | New York | NY | 10003 | 135564930 | 501(c)(3) | $22,500 | PUBLIC POLICY |
| John Hopkins University | |||||||
| 733 N Broadway | Baltimore | MD | 21205 | 520595110 | 501(c)(3) | $26,458 | TREAT ASIA |
| California Institute of Technology | |||||||
| 1200 E California Blvd | Pasadena | CA | 91125 | 951643307 | 501(c)(3) | $41,600 | BASIC RESEARCH |
| Case Western Reserve University | |||||||
| 10900 Euclid Avenue | Cleveland | OH | 44106 | 341018992 | 501(c)(3) | $41,666 | BASIC RESEARCH |
| Massachusetts General Hospital | |||||||
| 55 Fruit Street | Boston | MA | 02114 | 042697983 | 501(c)(3) | $41,666 | BASIC RESEARCH |
| The University of North Carolina at Chapel Hill | |||||||
| 104 Airport Dr | Chapel Hill | NC | 27599 | 566001393 | 501(c)(3) | $43,754 | BASIC RESEARCH |
| Emory University | |||||||
| 1599 Clifton Rd | Atlanta | GA | 303224250 | 580566256 | 501(c)(3) | $45,000 | BASIC RESEARCH |
| John Hopkins University | |||||||
| 733 N Broadway | Baltimore | MD | 21205 | 520595110 | 501(c)(3) | $45,571 | MSM INITIATIVES |
| Research Foundation for Mental Hygiene Inc | |||||||
| 1015 Riverside Drive | New York | NY | 10032 | 141410842 | 501(c)(3) | $50,000 | MSM INITIATIVES |
| Black AIDS Institute | |||||||
| 1833 West 8th St | Los Angeles | CA | 90057 | 954742741 | 501(c)(3) | $50,000 | PUBLIC POLICY |
| Beth Israel Deaconess Medical Center | |||||||
| 330 Brookline Avenue | Boston | MA | 02215 | 042103881 | 501(c)(3) | $50,361 | BASIC RESEARCH |
| New Hope for Cambodian Children | |||||||
| PO Box 2490 | Killeen | TX | 76549 | 205301015 | 501(c)(3) | $53,790 | TREAT ASIA |
| Harvard Medical School | |||||||
| 25 Shattuck Street | Southborough | MA | 01772 | 042697981 | 501(c)(3) | $59,600 | BASIC RESEARCH |
| Vaccine & Gene Therapy Institute of Florida | |||||||
| 9801 SW Discovery Way | Pt St Lucie | FL | 34987 | 364631835 | 501(c)(3) | $59,994 | BASIC RESEARCH |
| John Hopkins University School of Medicine | |||||||
| 733 N Broadway | Baltimore | MD | 21205 | 520595110 | 501(c)(3) | $59,999 | BASIC RESEARCH |
| Veterans Medical Research Foundation | |||||||
| 3350 La Jolla Village Drive mc 151 | San Diego | CA | 92161 | 330189397 | 501(c)(3) | $60,000 | BASIC RESEARCH |
| University of Washington | |||||||
| 4333 Brooklyn Ave NE | Seattle | WA | 98195 | 916001537 | 501(c)(3) | $60,000 | BASIC RESEARCH |
| Fred Hutchinson Cancer Research Center | |||||||
| 1100 Fairview Ave N | Seattle | WA | 98109 | 237156071 | 501(c)(3) | $62,502 | BASIC RESEARCH |
| Dana-Farber Cancer Institute Inc | |||||||
| 450 Brookline Ave | Boston | MA | 02215 | 042263040 | 501(c)(3) | $62,502 | BASIC RESEARCH |
| The Scripps Research Institute | |||||||
| 10550 N Torrey Pines Rd | La Jolla | CA | 92037 | 330435954 | 501(c)(3) | $62,502 | BASIC RESEARCH |
| Colorado State University | |||||||
| 408 Uni Svcs Ctr | Fort Collins | CO | 80523 | 846000545 | 501(c)(3) | $62,709 | BASIC RESEARCH |
| Oregon Health and Science University | |||||||
| 3181 SW Sam Jackson rd | Portland | OR | 97239 | 193176109 | 501(c)(3) | $66,527 | BASIC RESEARCH |
| Mount Sinai Beth Israel | |||||||
| 1st Ave at 16th St | New York | NY | 10003 | 135564934 | 501(c)(3) | $67,500 | PUBLIC POLICY |
| Vaccine & Gene Therapy Institute of Florida | |||||||
| 9801 SW Discovery Way | Pt St Lucie | FL | 34987 | 364631835 | 501(c)(3) | $74,940 | BASIC RESEARCH |
| Emory University | |||||||
| 954 Gatewood Road NE | Atlanta | GA | 30329 | 580566256 | 501(c)(3) | $75,000 | BASIC RESEARCH |
| Massachusetts General Hospital | |||||||
| 55 Fruit Street | Boston | MA | 02114 | 042697983 | 501(c)(3) | $75,000 | BASIC RESEARCH |
| The University of North Carolina at Chapel Hill | |||||||
| 104 Airport Dr | Chapel Hill | NC | 27599 | 566001393 | 501(c)(3) | $75,000 | BASIC RESEARCH |
| University of California Los Angeles | |||||||
| 11000 Kinross Ave | Los Angeles | CA | 90095 | 956006143 | 501(c)(3) | $75,000 | BASIC RESEARCH |
| University of Southern California | |||||||
| 2001 North Soto St | Los Angeles | CA | 90089 | 951642394 | 501(c)(3) | $90,000 | BASIC RESEARCH |
| Emory University | |||||||
| 1599 Clifton Rd | Atlanta | GA | 303224250 | 580566256 | 501(c)(3) | $90,000 | BASIC RESEARCH |
| Icahn School of Medicine at Mount Sinai | |||||||
| One Gustave Levy Place | New York | NY | 10029 | 136171197 | 501(c)(3) | $90,000 | BASIC RESEARCH |
| John Hopkins University | |||||||
| 733 N Broadway | Baltimore | MD | 21205 | 520595110 | 501(c)(3) | $90,000 | BASIC RESEARCH |
| John Hopkins University | |||||||
| 733 N Broadway | Baltimore | MD | 21205 | 520595110 | 501(c)(3) | $117,555 | BASIC RESEARCH |
| Oregon Health and Science University | |||||||
| 3181 SW Sam Jackson Rd | Portland | OR | 97239 | 931176109 | 501(c)(3) | $119,864 | BASIC RESEARCH |
| Vaccine & Gene Therapy Institute of Florida | |||||||
| 9801 SW Discovery Way | Pt St Lucie | FL | 34987 | 364631835 | 501(c)(3) | $119,957 | BASIC RESEARCH |
| Oregon Health and Science University | |||||||
| 3181 SW Sam Jackson Rd | Portland | OR | 97239 | 931176109 | 501(c)(3) | $119,994 | BASIC RESEARCH |
| John Hopkins University | |||||||
| 733 N Broadway | Baltimore | MD | 21205 | 520595110 | 501(c)(3) | $120,000 | BASIC RESEARCH |
| Vaccine & Gene Therapy Institute of Florida | |||||||
| 9801 SW Discovery Way | Pt St Lucie | FL | 34987 | 364631835 | 501(c)(3) | $120,000 | BASIC RESEARCH |
| Northwestern Unversity | |||||||
| 303 E Superior St | Chicago | IL | 60611 | 362167817 | 501(c)(3) | $120,000 | BASIC RESEARCH |
| Regents of the University of California | |||||||
| 3333 California St | San Francisco | CA | 94143 | 946036493 | 501(c)(3) | $120,000 | BASIC RESEARCH |
| John Hopkins University | |||||||
| 733 N Broadway | Baltimore | MD | 21205 | 520595110 | 501(c)(3) | $120,000 | BASIC RESEARCH |
| Case Western Reserve University | |||||||
| 10900 Euclid Ave | Cleveland | OH | 44106 | 341018992 | 501(c)(3) | $120,000 | BASIC RESEARCH |
| Blood Systems Inc | |||||||
| 270 Masonic Ave | San Francisco | CA | 94118 | 860098929 | 501(c)(3) | $126,580 | BASIC RESEARCH |
| Case Western Reserve University | |||||||
| 10900 Euclid Ave | Cleveland | OH | 44106 | 341018992 | 501(c)(3) | $140,507 | BASIC RESEARCH |
| Vaccine & Gene Therapy Institute of Florida | |||||||
| 9801 SW Discovery Way | Pt St Lucie | FL | 34987 | 364631835 | 501(c)(3) | $146,029 | BASIC RESEARCH |
| University of Pittsburgh | |||||||
| 123 University Place | Pittsburgh | PA | 15213 | 250965591 | 501(c)(3) | $167,804 | MSM INITIATIVES |
| Case Western Reserve University | |||||||
| 10900 Euclid Ave | Cleveland | OH | 44106 | 341018992 | 501(c)(3) | $185,130 | BASIC RESEARCH |
| The Brigham and Women's Hospital Inc | |||||||
| 75 Francis Street | Boston | MA | 02115 | 042312909 | 501(c)(3) | $191,039 | BASIC RESEARCH |
| University of California Los Angeles | |||||||
| 11000 Kinross Ave | Los Angeles | CA | 90095 | 956006143 | 501(c)(3) | $200,000 | BASIC RESEARCH |
| Massachusetts General Hospital | |||||||
| 55 Fruit Street | Boston | MA | 02114 | 042697983 | 501(c)(3) | $212,441 | BASIC RESEARCH |
| Case Western Reserve University | |||||||
| 10900 Euclid Ave | Cleveland | OH | 44106 | 341018992 | 501(c)(3) | $233,309 | BASIC RESEARCH |
| Vaccine & Gene Therapy Institute of Florida | |||||||
| 9801 SW Discovery Way | Pt St Lucie | FL | 34987 | 364631835 | 501(c)(3) | $393,524 | BASIC RESEARCH |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 63 | Total501c3OrgCnt |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | Grants and Assistance | FormAndLineReferenceDesc |
| Explanation | Part I, Line 2 amfAR provides grants and fellowships to independent not-for-profit organizations through a peer-review process. Grant applications are first reviewed by the Foundation's volunteer scientific advisory committee, which comprises recognized experts in the medical, scientific, and social sciences disciplines relevant to HIV and AIDS. The scientific advisory committee then sends its evaluations to one of the three committees (research, global initiatives or public policy) of the Foundation's program board, which serves in an advisory capacity to the Board of Trustees. After a program committee has completed its review of the applications, it presents its funding recommendations to amfAR's executive committee and/or the full Board of Trustees for final approval and funding authorization. Grants and fellowships are payable over a one-to-three-year period, and are revocable at amfAR's option if the recipient's performance or use of funds is not consistent with the terms of the grant or fellowships. In certain cases, the actual amounts paid under grants and fellowship awards may be less than the original award if the recipient does not use the full amount awarded. Therefore, a reserve for unexpended grants and fellowships has been recorded. Subawards are grants awarded to not-for-profit organizations to support the costs of collaboration and participation in HIV/AIDS-related research projects for which amfAR has secured restricted funds. Subawards are payable over a one-year period, although advance payments, in full or in part, may be issued following execution of the subaward agreement. Subawards are contingent upon the availability of funds and are revocable if the recipients' performance or use of funds is not consistent with the subaward terms. | ExplanationTxt |
Schedule J IRS990ScheduleJ
| Field | Value | IRS element (for citing) |
|---|---|---|
| Compensation Committee | Yes (X) | CompensationCommitteeInd |
| Independent Consultant | Yes (X) | IndependentConsultantInd |
| Compensation Survey | Yes (X) | CompensationSurveyInd |
| Board Or Committee Approval | Yes (X) | BoardOrCommitteeApprovalInd |
| Severance Payment | false | SeverancePaymentInd |
| Supplemental Nonqual Rtr Plan | Yes (true) | SupplementalNonqualRtrPlanInd |
| Equity Based Comp Arrngm | false | EquityBasedCompArrngmInd |
| Comp Based On Revenue Of Flng Org | false | CompBasedOnRevenueOfFlngOrgInd |
| Comp Bsd On Rev Related Orgs | false | CompBsdOnRevRelatedOrgsInd |
| Comp Bsd Net Earns Flng Org | false | CompBsdNetEarnsFlngOrgInd |
| Comp Bsd Net Earns Rltd Orgs | false | CompBsdNetEarnsRltdOrgsInd |
| Any Non Fixed Payments | false | AnyNonFixedPaymentsInd |
| Initial Contract Exception | false | InitialContractExceptionInd |
Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (15 entries)
| TitleTitleTxt | Base Compensation Filing OrgBaseCompensationFilingOrgAmt | Other Compensation Filing OrgOtherCompensationFilingOrgAmt | Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt | Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt | Total Compensation Filing OrgTotalCompensationFilingOrgAmt | Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt | Bonus Filing OrganizationBonusFilingOrganizationAmount |
|---|---|---|---|---|---|---|---|
| Kevin Frost | |||||||
| Chief Executive Officer | $374,093 | $37,373 | $94,850 | $45,331 | $551,647 | $37,373 | |
| Bradley Jensen | |||||||
| Assistant Treasurer, Cfo | $225,977 | $16,089 | $35,062 | $277,128 | |||
| John F Logan JD PhD | |||||||
| AssT Sec, Vp, GEN COUNSEL | $210,168 | $14,904 | $11,419 | $236,491 | |||
| Rowena Johnston | |||||||
| AsSt Secretary, Vice PresIDENT | $173,783 | $12,205 | $11,419 | $197,407 | |||
| Edward Donnelly | |||||||
| Asst Treasurer, ControlleR | $139,447 | $10,188 | $10,476 | $160,111 | |||
| Eric Muscatell | |||||||
| Vice President of Development | $164,114 | $0 | $11,727 | $11,419 | $187,260 | $0 | |
| Christopher Collins | |||||||
| Vice President, Public Policy | $190,478 | $13,483 | $35,062 | $239,023 | |||
| Annette Sohn | |||||||
| Vice President, TREAT Asia PGM | $200,792 | $14,505 | $5,576 | $220,873 | |||
| AnnMarie Shannahan | |||||||
| Vice President, Public Info. | $200,861 | $14,150 | $11,419 | $226,430 | |||
| Andrew McInness | |||||||
| Director, Publications | $142,695 | $10,271 | $35,062 | $188,028 | |||
| Anthony Ancona | |||||||
| Vice President, Human Resource | $158,957 | $11,373 | $11,419 | $181,749 | |||
| Susan Doster | |||||||
| Chief Technology Officer | $132,756 | $9,604 | $15,885 | $158,245 | |||
| Bennah Serfaty | |||||||
| Sr Director of CommunicatiON | $113,800 | $8,164 | $35,062 | $157,026 | |||
| Raoul Norman Tenazas | |||||||
| Creative Director | $110,187 | $8,037 | $35,062 | $153,286 | |||
| GREGORY L BOROFF | |||||||
| VP, DEVELOPMENT | $155,189 | $11,017 | $6,632 | $172,838 | |||
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | Compensation | FormAndLineReferenceDesc |
| Explanation | Part I, Line 4 Chief Executive Officer, Kevin Frost, participated in a supplemental nonqualified retirement plan. Amfar contributed $59,500 into Mr. Frost's non-qualified retirement plan; in additon mr. Frost received $37,373 distribution from the plan that is reported in column (b)(iii). | ExplanationTxt |
Schedule M IRS990ScheduleM
| Field | Value | IRS element (for citing) |
|---|---|---|
| Works Of Art | WorksOfArtGrp | |
| Art Historical Treasures | ArtHistoricalTreasuresGrp | |
| Art Fractional Interest | ArtFractionalInterestGrp | |
| Books And Publications | BooksAndPublicationsGrp | |
| Clothing And Household Goods | ClothingAndHouseholdGoodsGrp | |
| Cars And Other Vehicles | CarsAndOtherVehiclesGrp | |
| Boats And Planes | BoatsAndPlanesGrp | |
| Intellectual Property | IntellectualPropertyGrp |
Securities Publicly Traded SecuritiesPubliclyTradedGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Non Cash Checkbox | Yes (X) | NonCashCheckboxInd |
| Contribution | 18 | ContributionCnt |
| Noncash Contributions Rpt F990 | $199,065 | NoncashContributionsRptF990Amt |
| Method Of Determining Revenues | sales price | MethodOfDeterminingRevenuesTxt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities Closely Held Stock | SecuritiesCloselyHeldStockGrp | |
| Secur Prtnrshp Trust Intrsts | SecurPrtnrshpTrustIntrstsGrp | |
| Securities Miscellaneous | SecuritiesMiscellaneousGrp | |
| Qualified Contrib Hist Struct | QualifiedContribHistStructGrp | |
| Qualified Contrib Other | QualifiedContribOtherGrp | |
| Real Estate Residential | RealEstateResidentialGrp | |
| Real Estate Commercial | RealEstateCommercialGrp | |
| Real Estate Other | RealEstateOtherGrp | |
| Collectibles | CollectiblesGrp | |
| Food Inventory | FoodInventoryGrp | |
| Drugs And Medical Supplies | DrugsAndMedicalSuppliesGrp | |
| Taxidermy | TaxidermyGrp | |
| Historical Artifacts | HistoricalArtifactsGrp | |
| Scientific Specimens | ScientificSpecimensGrp | |
| Archaeological Artifacts | ArchaeologicalArtifactsGrp | |
| Any Property That Must Be Held | false | AnyPropertyThatMustBeHeldInd |
| Review Process Unusual NC Gifts | Yes (true) | ReviewProcessUnusualNCGiftsInd |
| Third Parties Used | false | ThirdPartiesUsedInd |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | Form 990, Schedule M, line 31 | FormAndLineReferenceDesc |
| Explanation | To the extent that amFAR receives non-standard contributions, the organization's policy is to liquidate those items into cash for eventual use in support of the organization's mission. | ExplanationTxt |
Schedule O IRS990ScheduleO
Supplemental Information Detail SupplementalInformationDetail (9 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| Program Service Accomplishments(1) | Part III, Line 4a-4d(1) Line 4a: Research: amfAR supports research projects that explore novel approaches to scientifically sound but untested hypotheses in all areas of research on HIV/AIDS, funding goal-oriented studies that often lack the preliminary data required for support from traditional grant-makers. The Foundation plays a vital role in HIV/AIDS research, identifying critical gaps in knowledge and providing essential seed money that enables grantees and fellows to test the merits of new concepts or technologies that subsequently can be validated through large-scale studies, such as those funded by the U.S. National Institutes of Health. amfAR fellowships allow talented young investigators to conduct original investigations under the guidance of experienced scientists, helping to ensure the long-term vitality of AIDS research. New Grants and Fellowships Grants and fellowships are awarded through a rigorous process of peer review by a team of independent HIV/AIDS experts drawn largely from the volunteer scientists on amfAR's Scientific Advisory Committee. Guided by its scientific advisors and with the approval of its board of trustees, amfAR pursues a strategic research plan that focuses on the treatment, prevention, and cure of HIV/AIDS. In FY2014, amfAR awarded nearly $7 million in grants and fellowships to support 34 research projects. Six researchers received Mathilde Krim Fellowships in Basic Biomedical Research, an initiative that provides funding for exceptional young researchers who are new to the field of HIV/AIDS research. The initiative has already achieved spectacular results, including numerous published studies in major scientific journals. The 2014 Krim Fellows-each of whom received $150,000-are working on projects focused on HIV/AIDS cure and epidemiological research and vaccine and treatment development. Among the 2014 fellows is Dr. Damien Tully of Massachusetts General Hospital, Cambridge, MA, who is using his amfAR funding to study tissue from mouse models and recently infected people to better understand how the virus spreads once infection occurs. HIV is usually transmitted through mucosal membranes, such as at the vagina or rectum, but eventually the virus wreaks its havoc in the intestines. Under the guidance of mentor Dr. Todd Allen, Dr. Tully aims to understand how the virus spreads and evolves in the body and to generate vital information for the development of a vaccine and possibly a cure. Cure-Focused Studies The search for a cure for HIV/AIDS is at the center of amfAR's research efforts. In FY2014, through the amfAR Research Consortium on HIV Eradication (ARCHE) program and other targeted grants, the Foundation awarded over $6 million toward cure-focused research. Countdown to a Cure for AIDS In February 2014, amfAR launched the Countdown to a Cure for AIDS, a research initiative aimed at developing the scientific basis for a cure for HIV by 2020. In support of the Countdown, amfAR plans to strategically invest $100 million in cure research over the next six years. amfAR Research Consortium on HIV Eradication The Foundation launched ARCHE in 2010 to encourage teams of distinguished scientists from across the globe to work collaboratively on cure-focused research and to provide them with the resources to do so. Since its inception, ARCHE funding has supported the work of 86 research teams pursuing cure-focused studies at 51 institutions on five continents. In July, more than $2.4 million in funding went to seven collaborative teams of researchers working in countries including the United States, the United Kingdom, the Netherlands, Finland, France, Germany, Spain, Sweden, Thailand, and Australia on studies exploring potential strategies for characterizing viral reservoirs-a major obstacle to a cure-and eliminating HIV infection from the body. The largest award in this round of grants is supporting a consortium of European researchers studying the outcomes of HIV patients who undergo different types of stem cell transplants. Timothy Brown, the first and only person known to have been cured of HIV, received a stem cell transplant from a donor with a rare genetic mutation conferring resistance to HIV infection. The research team, led by Dr. Javier Martinez-Picado of Irsi Caixa in Spain and Dr. Annemarie Wensing of University Medical Center Utrecht in the Netherlands, anticipate having several HIV patients in need of stem cell transplants and hope to generate new knowledge that can inform more widely applicable interventions. A team of researchers in the U.S. will receive funding to address one of the most pressing challenges in HIV research: determining whether people whose HIV has dropped to an undetectable level have been cured, or whether current tests are simply not sensitive enough to detect every last remnant of virus. In a recent amfAR-funded study, Dr. Timothy Henrich of Brigham and Women's Hospital in Boston described two patients who had received stem cell transplants to treat their cancer and in whom HIV could no longer be detected using the most sophisticated tests currently available. When the patients stopped taking antiretroviral therapy, their virus eventually returned, indicating that they had not been cured. Dr. Henrich is collaborating with Dr. Ramesh Akkina of Colorado State University in an effort to infuse cells taken from the Boston patients prior to viral rebound into mice engineered to contain human immune systems. If the mice become infected, this would represent a more sensitive test of HIV persistence than any other test currently available. Targeted Grants for HIV Cure Research In February 2014, amfAR awarded 12 targeted grants totaling more than $2.15 million to leading researchers from around the world who are working on a variety of cutting-edge, cure-focused studies. These projects include research aimed at therapeutic vaccine development, expanding our understanding of latent viral reservoirs, and examining pharmacological and gene therapy approaches to curing HIV. Dr. Nancy Haigwood and her colleagues at Oregon Health and Science University in Portland are testing the ability of antibodies to limit the establishment of the viral reservoir in newborns infected with HIV. In a study that could inform our understanding of how and when the reservoir is established, Dr. Haigwood's team is testing in infant macaques the effects of antibodies found to be effective in controlling HIV in humans. At the University of California, San Francisco, Dr. Hiroyu Hatano and colleagues are recruiting subjects from ongoing studies of PrEP (pre-exposure prophylaxis). Because these study participants are frequently tested for HIV, Dr. Hatano believes her team will be able to identify subjects in the first couple of weeks of infection, when the viral reservoirs are established. This will allow the researchers to discover which cells HIV infects at various stages during acute infection and how very early treatment might affect the size or distribution of the reservoir. A team of researchers at the University of Toronto led by Dr. Mario Ostrowski is pursuing an entirely different strategy: therapeutic vaccination. Dr. Ostrowski and colleagues are conducting a small pilot clinical trial of a therapeutic vaccine to determine whether it can reduce the size of the reservoir. The vaccine will be tested in subjects who started antiretroviral therapy within six months of acquiring HIV and is intended to induce cellular immunity, one arm of the immune system responsible for killing cells that are infected with the virus. Published Research Research studies make the greatest impact on the AIDS field and on the broader scientific community when they are published in scientific journals. In the past year, at least 49 scientific publications resulted from amfAR-funded research. Killer Immunity and HIV Reservoirs In the January issue of the Journal of Acquired Immune Deficiency Syndromes, amfAR grantee Dr. Mathias Lichterfeld reported on the immune responses of "elite controllers," people infected with HIV but capable of maintaining low viral loads and high T cell counts without the aid of antiretroviral therapy. Dr. Lichterfeld, working at Harvard University and Massachusetts General Hospital, along with colleagues there and at China Medical University in Shenyang, focused on a major player in the T cell immune system: the CD8+ cytotoxic cell. These "killer T cells" are capable of destroying cells infected with viruses. The research team found that the CD8+ T cells' ability to kill HIV-infected cells was significantly greater in elite controllers than in patients requiring antiretroviral therapy to suppress virus. Of even greater interest, further studies showed a consistent relationship among a genetic marker called MHC-1 B57, high killer T cell activity, and low virus reservoir. In addition, the effect was most pronounced in nave T cells-a type of immune cell that constitutes the reservoir but has |
| Program Service Accomplishments (2) | Part III, Line 4a-4d (2) Line 4b: TREAT ASIA: amfAR's TREAT Asia program (Therapeutics Research, Education, and AIDS Training in Asia) is a network of hospitals, clinics, and research institutions working with civil society to ensure the safe and effective delivery of HIV/AIDS treatments across Asia and the Pacific. The TREAT Asia Network encompasses 21 adult and 18 pediatric sites throughout the region, which collaborate on a variety of projects. TREAT Asia HIV Observational Database (TAHOD) TREAT Asia pioneered the region's first adult observational database for HIV/AIDS, which now includes anonymous data collected from approximately 9,000 patients at 21 clinical sites in 12 countries. The information gathered and analysed through the database informs the development of more effective research and treatment programs, and helps define treatment standards specific to HIV/AIDS in Asia. In FY2014, the TAHOD network launched a multi-site clinical study in Asia that addresses obstacles to treating hepatitis C among those co-infected with HIV in four countries: Indonesia, Malaysia, Thailand, and Vietnam. The study began with a screening to assess how many HIV-positive patients in TREAT Asia participating clinics in these countries needed to start treatment for hepatitis C. At the end of September, the study had enrolled approximately 135 patients in treatment, and will continue to enroll up to 200 patients. The study aims to develop a pilot model of care for treating hepatitis C in resource-limited settings that can be replicated throughout the region, where treatment for the disease is costly and often inaccessible. International AIDS Database TREAT Asia manages the Asia-Pacific section of the International Epidemiologic Databases to Evaluate AIDS (IeDEA), a global collaboration established by the U.S. National Institute of Allergy and Infectious Diseases. TREAT Asia Pediatric Network TREAT Asia's Pediatric Network includes 18 sites in six countries; these sites share information and best practices in an effort to improve the quality of pediatric care in the region. The TREAT Asia Pediatric HIV Observational Database (TApHOD) was modeled on the adult database and includes data from approximately 5,500 pediatric patients at 18 clinical sites in Cambodia, India, Indonesia, Malaysia, Thailand, and Vietnam. In FY2014, the TREAT Asia Studies to Evaluate Resistance, Pediatrics (TASER-P) completed core activities of a three-year study on how children and adolescents who had developed resistance to first-line antiretrovirals (ARV) responded and adhered to second-line treatment. Ongoing analysis has provided insights into how to improve long-term ARV management in children and adolescents. TREAT Asia will continue to follow approximately 60 children who have developed resistance to second-line treatment for another two years in order to better understand which third-line ARVs will be most needed in the region. Adolescent Research In FY2014, TREAT Asia conducted several studies on how HIV affects adolescents physically, socially, and emotionally. TREAT Asia's pediatric sites conducted local studies among their adolescent HIV patients to investigate HIV's impact on their health and developmental needs. Among other issues, they investigated adolescents' reproductive and sexual health needs, liver function, treatment failure, treatment adherence, and the impact of orphanhood, disclosure, and school attendance on antiretroviral outcomes. In addition, TREAT Asia is conducting an ongoing study using an audio-computer-assisted survey instrument (ACASI) to better understand how adolescents experience living with HIV by allowing them to anonymously respond to questions using a computer interface about whether they are taking their medicines; if they have tried alcohol, tobacco, or other drugs; their sexual behavior; and stigma they may have experienced at school or at home. Exploring Links Between HIV and Cancer Among HIV-positive men who have sex with men (MSM), the risk of anal cancer is twice the level of those who are HIV-negative, but little research has been done on this issue in Asia. In 2009, using funding from IeDEA, TREAT Asia began supporting an innovative research study exploring the links between HIV and anal cancer and looking at cancer biomarkers in an attempt to better identify MSM with pre-cancerous anal lesions. Research on human papillomavirus (HPV) and anal cancer risk among MSM is ongoing at sites in Bangkok, Bali, and Jakarta. Building Research and Treatment Capacity TREAT Asia has implemented a research education program to help network members strengthen their skills in conducting clinical research and to boost the overall quality of care in the region. TREAT Asia organized 10 workshops and training sessions in FY2014, including sessions for health providers on managing HIV and hepatitis C co-infection, treating men who have sex with men, clinical management of pediatric HIV, rights and legal protections for women living with HIV, and communication skills to promote early HIV testing and treatment. Building Community Treatment Literacy and Promoting Advocacy for Treatment Access Communicating treatment information about a disease as complex as HIV/AIDS can be daunting, but patients' lives depend on it. TREAT Asia works closely with regional organizations to support treatment literacy activities, including the production of "community-friendly" educational brochures on HIV treatment standards in local languages. In FY2014, TREAT Asia developed three fictional videos on the sexual and reproductive health and rights of women living with HIV that provide examples of both positive and negative advice that HIV-positive pregnant women might receive from healthcare professionals. The videos are in Thai and have English subtitles. They are available on TREAT Asia's webpage and its public YouTube channel. In addition, TREAT Asia released a policy brief titled Hepatitis C and HIV: Addressing the Dual Epidemic, which summarizes hepatitis C disease progression, treatment, and advocacy priorities. It also produced a fact sheet providing a summary of the key recommendations in the first World Health Organization guidelines on the screening, care, and treatment of persons with hepatitis C infection. TREAT Asia also held a regional meeting on improving access to hepatitis C treatment, which was attended by 20 advocates from six South and Southeast Asian countries. TREAT Asia also continued to publish lay-language articles on AIDS research, policy, and community issues facing the TREAT Asia network and the Asia-Pacific as a whole. The articles appear in the TREAT Asia Report, a bimonthly e-newsletter, and on TREAT Asia's website, www.treatasia.org. 20th International AIDS Conference TREAT Asia was well represented at the main and pre-conference events in July 2014 in Melbourne, Australia. TREAT Asia staff and network investigators participated in pre-conference workshops on HIV pediatric and HIV cure research. At the pediatric workshop, presentations were made on two TREAT Asia studies and one IeDEA multi-regional analysis (duration of initial antiretroviral therapy). At the main conference, additional TREAT Asia studies were presented on adherence to treatment and experiences of stigma among adolescents, hepatitis C co-infection and liver disease, and 10-year treatment outcomes in TREAT Asia's regional adult HIV cohort. Dr. Annette Sohn, amfAR vice president and director of the TREAT Asia program, was invited to give oral presentations on key at-risk populations in Asia, non-communicable diseases in resource-limited settings, and pediatric and adolescent HIV. |
| Program Service Accomplishments (3) | Part III, Line 4a-4d (3) Line 4c: EDUCATION AND INFORMATION: amfAR seeks to translate and disseminate information on important AIDS-related research, treatment, prevention, and policy issues for diverse audiences and to increase broad awareness and knowledge of the pandemic. amfAR also publishes a wide range of educational materials, maintains an informative website, and engages respected public figures, HIV/AIDS scientists, and policymakers in communicating the need for continued research to develop new methods of prevention, treatment, and, ultimately, a cure for AIDS. Educational Materials amfAR produces a range of periodicals in both print and electronic formats, including its newsletter Innovations, published twice a year and distributed to more than 45,000 people; the TREAT Asia Report, an e-mail newsletter distributed six times a year to more than 4,000 readers in the international health community; and a monthly e-mail newsletter distributed to nearly 100,000 people. The Foundation's website features news, interviews, blog posts, and other original articles covering science, policy, the global epidemic, and amfAR programs and activities. amfAR also creates and distributes program reports, press releases, and updates on major HIV/AIDS issues, and conducts public service advertising campaigns that have been instrumental in educating policymakers, healthcare professionals, people living with HIV/AIDS, and the general public. Social Media amfAR vigorously expanded its presence in the social media arena, reaching large numbers of people, including a younger demographic that is often less educated about HIV and the AIDS epidemic. The Foundation regularly added content to its Facebook page and live tweeted and posted images on Instagram from fundraising and program events. amfAR has 57,000 likes on Facebook, 29,000 Twitter followers, and nearly 33,000 Instagram followers. Media Outreach amfAR continued to work closely with the media to raise the profile of HIV/AIDS, both domestically and internationally, and to help ensure the accuracy of AIDS-related press coverage. Articles and reports involving amfAR-many of which included interviews with amfAR spokespeople-were carried in numerous media outlets, including the New York Times, The Wall Street Journal, The Washington Post, and The Huffington Post, and news agencies such as the Associated Press, CNN, Bloomberg News, and Reuters. amfAR's public awareness efforts are greatly enhanced by the committed support of public figures who lend their voices and donate their time, talents, and resources to help sustain the Foundation's mission. Support of amfAR by prominent public figures began with the late Dame Elizabeth Taylor, and others have followed in her footsteps. amfAR is profoundly grateful for the continuing steadfast support of Global Fundraising Chairman Sharon Stone. In FY2014, celebrity supporters included amfAR Ambassadors Cheyenne Jackson, Janet Jackson, Milla Jovovich, Liza Minnelli, and Michelle Yeoh, as well as Dame Shirley Bassey, Justin Bieber, Mary J. Blige, Jessica Chastain, Sofia Coppola, Alan Cumming, Willem Dafoe, Leonardo DiCaprio, Jane Fonda, Grace Jones, Heidi Klum, Julianna Margulies, Kylie Minogue, Aishwarya Rai and Abhishek Bachchan, Lana Del Rey, Michelle Rodriguez, Diana Ross, and Dita Von Teese, among many others. |
| Program Service Accomplishments (4) | Part III, Line 4a-4d (4) THE GMT INITIATIVE: Since 2007, amfAR has been serving the HIV-related needs of gay men, other men who have sex with men (MSM), and transgender individuals (collectively, GMT) throughout the developing world through its GMT Initiative. Through small, targeted grants to grassroots groups, amfAR helps expand access to HIV education and prevention services; supports advocacy aimed at increasing funding for prevention and treatment services; and works to end the stigma, discrimination, and violence that threaten the lives of GMT and fuel the spread of HIV/AIDS. Community Awards In FY2014, amfAR awarded approximately $300,000 to 15 groups in Africa and Latin America for a wide range of projects addressing HIV prevention, outreach, education, advocacy, testing, research, and capacity building. Sample funded projects include: Africa Alternatives-Cameroun (Douala, Cameroon) Alternatives used its fifth year of GMT Initiative support to integrate peer-led strategies with clinical services to increase LGBT individuals' access to HIV prevention, care, and treatment in Douala. Alternatives mobilized their peer educators across the city to hold discussions on HIV/AIDS and STI prevention and treatment, while also promoting the services at its Access Center to increase the patient roster. In addition to the comprehensive medical services offered at the Access Center, Alternatives offered mobile testing and organized testing awareness days to reach a broader number of LGBT through HIV testing. Action Humanitaire Pour la Sant et le Dveloppement Communautaire (AHUSADEC) (Bukavu, Democratic Republic of the Congo) In its second year of amfAR support, AHUSADEC improved its referral system for GMT-friendly public healthcare centers in Bukavu to improve the ability of GMT to access health services and HIV testing and treatment. It also empowered GMT sex workers by providing HIV prevention information. In addition, AHUSADEC hosted training workshops for healthcare workers at the GMT-friendly testing centers to ensure a stigma-free environment and launched a media campaign addressing HIV-related issues. Latin America Asociacin de Travestis, Transexuales, y Transgeneros de Argentina Asociacin Civil (ATTTA) (Buenos Aires, Argentina) ATTTA conducted a survey on attitudes, behaviors, and practices regarding sexual health and HIV prevention and risks for 180 transgender women and 40 of their stable partners in Buenos Aires, Argentina. The survey results were used to establish baseline behavioral data to inform policies and programs for transgender women. In addition, ATTTA established baseline HIV prevalence data by offering rapid HIV testing and counseling to all clients seeking services at their mobile health unit. The group also evaluated the acceptability of these services and referred all those with positive results directly to partner clinics. Red Nacional de Mujeres Travestis, Transexuales y Transgeneros de Bolivia (RED TREBOL) (Cochabamba, Bolivia) RED TREBOL used its third consecutive grant from amfAR to create the first trans-specific health center in Cochabamba. RED TREBOL established a physical space for the clinic and began to train peer educators to promote the clinic and its services and distribute referrals for the clinic to create demand. A medical team that provides services for RED TREBOL at their mobile unit program began offering HIV testing and counseling, hormones and hormonal guidance, STI prevention and treatment services, and mental health services at the clinic. "In Action" Awards Using two-year funding from the Arcus Foundation, the GMT Initiative supported four organizations as part of its Advocacy in Action program, which engages GMT-led community-based organizations that wish to influence the policies of governments and external donors. Ten organizations were supported through its Evidence in Action program, which documents and evaluates the impact of community-based programs with the ultimate goal of implementing the most workable strategies for stopping the spread of HIV/AIDS. Evidence in Action was developed with support from ViiV Healthcare's Positive Action Program and the Elton John AIDS Foundation. Publications As part of its efforts to raise awareness among governments, donors, and international nongovernmental organizations about the spread of HIV among GMT individuals and to advocate for effective strategies to address it, amfAR publishes reports on HIV and GMT. In FY2014, the GMT Initiative published two reports in its "Lessons from the Front Lines" series. The first, Lessons From the Front Lines: Research Impact Analysis, outlined some of the most successful community-led research studies GMT grantee partners have implemented to improve HIV testing, treatment, and awareness in five regions-Africa, Asia-Pacific, the Caribbean, Eastern Europe and Central Asia, and Latin America. The second, Lessons From the Front Lines: Trans Health and Rights, produced in collaboration with Global Action for Trans Equality (GATE), examined the challenges faced by 10 grantee partners-many of which were led by transgender individuals-and assessed their progress. The GMT Initiative also created a series of fact sheets in English, French, and Spanish on emerging HIV prevention technologies that explain each technology and serve as a tool to help GMT advocates advocate for the interventions' increased availability worldwide. Symposia and Conferences In January 2014, the GMT Initiative supported and attended a meeting hosted by the University of West Indies (UWI) and Columbia University engaging GMT community organization grantee partners, researchers, government officials, and other key stakeholders to develop a formalized GMT-related research agenda for Jamaica. Based on a similar program amfAR funded in South Africa, UWI and Columbia University used the meeting to formulate a research plan for submission to the U.S. National Institutes of Health for funding. In May, amfAR partnered with the Gay and Lesbian Coalition of Kenya (GALCK) and the International AIDS Vaccine Initiative (IAVI) to sponsor a meeting between LGBT community members and social/behavioral researchers in Kenya to formulate a community-led research agenda on LGBT health. The GMT Initiative played an active role at the 2014 International AIDS Conference and the MSM pre-conference in Melbourne, Australia. Eighteen GMT activists and grantee partners received support from amfAR to attend the conference. All had at least one presentation during the conference, with many speaking on multiple panels and poster sessions. GMT Initiative staff convened nine sessions on topics including the results and lessons learned from its Evidence in Action program, transgender health and rights, information and communication technology use in HIV efforts targeting GMT individuals, lubricant access, and safety and security in conducting HIV research with GMT in rights-constrained settings. In addition, the GMT Initiative hosted a donor meeting on transgender issues and a grantee exchange meeting (in conjunction with the Public Policy office) for 24 representatives from current grantee partners. |
| Program Service Accomplishments (5) | Part III, Line 4a-4d (5) public policy: Informed by thorough research and analysis, amfAR is a highly respected advocate of rational and compassionate AIDS-related public policy. The Foundation is engaged in efforts to secure necessary increases in funding for HIV/AIDS research; implement the U.S. National HIV/AIDS Strategy; expand access to care and treatment; and protect the civil rights of all people affected by HIV/AIDS. Capitol Hill Briefings The Role of HIV Research in Ending AIDS: New Developments in HIV Vaccine and Prevention Science, November 18, 2013 amfAR co-sponsored this briefing with AVAC: Global Advocacy for HIV Prevention, the Center for Global Health Policy, and the International AIDS Vaccine Initiative, in cooperation with Congresswoman Barbara Lee. Speakers included Carl Dieffenbach, director of NIAID's Division of AIDS; Fred Sawe, deputy director of Kenya Medical Research Institute/Walter Reed Project; Christina Polyak, research physician at the Military HIV Research Program, Walter Reed Army Institute of Research; and Margaret McGlynn, president and chief executive officer of the International AIDS Vaccine Initiative. Christine Lubinski, executive director of the Center for Global Health Policy, and Kevin Fisher, policy director of AVAC: Global Advocacy for HIV Prevention, acted as moderators. Making AIDS History: From Science to Solutions, April 30, 2014 amfAR convened a panel of leading government, research, policy, and advocacy experts in Washington, D.C., to discuss recent progress in the fight against HIV/AIDS, both domestically and globally. Participants included Dr. Jim Yong Kim, president of the World Bank Group; Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health; Dr. Deborah Birx, Ambassador-at-Large and U.S. Global AIDS Coordinator; Michel Sidib, executive director of UNAIDS; Judy Woodruff, co-anchor of PBS NewsHour; Dr. Paul Farmer, co-founder of Partners in Health and chair of Harvard Medical School's Department of Global Health and Social Medicine; and Douglas Brooks, director of the White House Office of National AIDS Policy; among others. Members of Congress, including House Democratic Leader Nancy Pelosi, Senator Tom Harkin, and Congressman Jim Himes, also spoke at the briefing organized by Dr. Susan Blumenthal, amfAR's senior policy and medical advisor and former U.S. Assistant Surgeon General. Shaping the Domestic Response to HIV/AIDS amfAR has long advocated the implementation of a comprehensive national HIV/AIDS strategy to address the epidemic in the U.S., where more than 1 million people are living with the virus. In FY2014, amfAR produced a number of opinion pieces, issue briefs, special reports, and infographics addressing important domestic topics, such as funding for AIDS research and U.S. HIV/AIDS programs, Medicaid expansion's effect on HIV health services in the U.S., and HIV prevention among key populations, specifically transgender individuals and black MSM. In December 2013, amfAR partnered with the Treatment Action Group (TAG) to issue a report titled Filling the Gaps in the U.S. HIV Treatment Cascade: Developing a Community Driven Research Agenda that outlined research needed to improve outcomes on the domestic HIV treatment cascade and ensure more people are engaged and retained in HIV care. The two groups then jointly held a series of meetings with government officials on next steps to enact the agenda. As one of the earliest supporters of comprehensive harm reduction programs for people who inject drugs (PWID), including syringe exchange, amfAR has played a leading role in advocating the implementation of these lifesaving HIV prevention programs. In FY2014, amfAR continued to advocate overturning the ban on federal funding of syringe services programs. Global Health amfAR produced a special report with AVAC: Global Advocacy for HIV Prevention outlining the need for a new approach to tracking data to guide the key decisions that shape the global response to the HIV/AIDS epidemic. The report, titled Data Watch: Closing a Persistent Gap in the AIDS Response, updates amfAR's and AVAC's 2012 Action Agenda to End AIDS, which made the case for a more businesslike approach to ending the epidemic and proposed a multi-year plan with concrete strategies, targets, and timelines. amfAR also partnered with AVAC to place an opinion piece written by Chris Collins, former amfAR vice president and director of Public Policy, and Mitchell Warren, executive director of AVAC, titled "Time to Tip the Scales in Favor of Ending AIDS" in the Huffington Post to accompany the report. The editorial was also posted on POZ.com and the Kaiser Daily Summary. Additionally, in FY2014, amfAR reported on the need for funding for the global AIDS response through opinion pieces, issue briefs, and infographics, with specific attention to how funding cuts to the President's Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund to Fight AIDS, Tuberculosis and Malaria would undermine a decade's worth of progress in scaling up treatment and care. In January 2014, Dr. Susan Blumenthal, amfAR senior policy and medical advisor, placed an opinion piece in the Huffington Post titled "Our Shared Responsibility: Ending AIDS, Tuberculosis, and Malaria." Public Policy also continued to advocate for sound, evidence-based policies to address HIV among key populations globally. In FY2014, Kali Lindsey, deputy director of the Public Policy Office, traveled to Kenya and Vietnam to discuss efforts to scale up access to syringe exchange, methadone, and ARV for PWID. Gay men, other men who have sex with men, and transgender individuals-collectively referred to as GMT-remain one of the hardest hit and most underserved populations in the global HIV/AIDS epidemic. amfAR's policy office works closely with the Foundation's GMT Initiative to advocate for expanded access to HIV prevention and treatment services for GMT worldwide, and to fight the stigma and discrimination that make GMT more vulnerable to HIV infection and inhibit equal access to care. In March, amfAR Founding Chairman Dr. Mathilde Krim and amfAR Trustee Harry Belafonte expressed their grave concern over new anti-LGBT laws in Uganda and Nigeria in an opinion piece for CNN.com. |
| Policies | form 990, part vi, section b Line 11 - The Form 990 was prepared by a nationally renowned accounting firm in conjunction with the organization's financial department. A copy of the draft Form 990 was circulated to the full Board of Trustees for discussion and comment. Each Board Member was provided ample opportunity to comment on the information contained in the 990 prior to its filing with the Internal Revenue Service. Line 12 - Each officer, director, trustee and key employee of amFar ("foundation") is required to annually disclose any conflicts of interest that arise by virtue of employment, board service, or position with the foundation. The foundation monitors compliance with its conflict of interest policy through an annual questionnaire/disclosure statement that is distributed to these individuals. Potential conflicts are investigated immediately. LINE 15 -AMFAR ("FOUNDATION FOR AIDS RESEARCH") UNDERTAKES A THOROUGH PROCESS TO ENSURE THAT THE COMPENSATION IT PAYS TO ITS TOP MANAGEMENT OFFICIAL AND ALL OF ITS OFFICERS AND KEY EMPLOYEES IS REASONABLE GIVEN THE MARKET IN WHICH THE FOUNDATION OPERATES. AN INDEPENDENT CONSULTING FIRM QUALIFIED IN THE AREA OF NONPROFIT COMPENSATION PREPARES AN ANALYSIS OF MARKET COMPENSATION RANGES BY JOB FUNCTION AND PRESENTS IT TO THE COMPENSATION COMMITTEE OF THE BOARD. ON THE BASIS OF THIS INFORMATION, STAFF COMPENSATION IS DETERMINED ACCORDING TO SALARY RANGES APPROVED BY THE COMPENSATION COMMITTEE OF THE BOARD, IN CONSULTATION WITH THE CEO AND CFO. CEO COMPENSATION IS REVIEWED AND DETERMINED BY THE COMPENSATION COMMITTEE OF THE BOARD UTILIZING THE INDEPENDENT CONSULTANT ANALYSIS. |
| Disclosure | Form 990, Part VI, Section C LIne 19 - amfar makes its Form 990 available to the public by retaining a copy at its place of business and on its website, www.amfar.org. The Form 990 is likewise published on the internet at www.guidestar.org. The Foundation's financial statements are made available in its annual report and on its website. The Foundation's governing documents and conflict of interest policy are not ordinarily made available to the public, but, if requested, will be provided at management's discretion. |
| Functional Expenses | Part IX, Lines 1 & 3 The Foundation for AIDS Research reports its grants net of grant returns or recoveries. Periodically, grants remitted to charitable organizations are returned to AMFAR for a variety of reason. On Schedules F & I, grants are reported irrespective of whether they were ultimately returned to AMFAR since categorizing the "returned" amounts would be time consuming. Therefore, amounts reported on Part IX, Line 1 will not tie to total grants on Schedule I; amounts reported on Part IX, Line 3 will not tie to total grants on Schedule F. |
| Other Changes in Net Assets | FORM 990, SECTION XI, LINE 5 CHANGE IN VALUE OF THIRD PARTY TRUST............($33,603) --------- TOTAL LINE 9 ($33,603) |
Comments